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ABSTRACT(
Pre- and perinatal environmental factors have been associated with increased 
schizophrenia risk, particularly in combination with genetic liability. Both low 
and high birth weight have been associated with an increased risk of autism 
spectrum disorders and schizophrenia. The interaction of specific 
schizophrenia susceptibility genes and specified pre- and perinatal 
environmental factors have recently been described in relation to augmented 
schizophrenia risk.     
In this thesis, the relationship between birth weight and schizophrenia risk 
was investigated as part of a large Finnish schizophrenia family study sample 
based on the “Genetic Epidemiology and Molecular Genetics of Schizophrenia 
in Finland” study, in which genetic susceptibility for schizophrenia is known 
to be elevated relative to the general population (Study I). The study sample 
consisted of two subsamples having at least one sibling with a diagnosis of 
schizophrenia. The associations between birth weight and symptom severity 
of schizophrenia and psychotic disorders (Study II) and cognitive functioning 
in schizophrenia (Study III) were also characterized. A gene-environment 
interaction, focusing on birth weight and specific genes from the DISC1 
network (Study IV), which had previously been found to be associated with 
increased schizophrenia risk in the same cohort, was also investigated in 
relation to schizophrenia risk. 
A 1.68-fold increase in schizophrenia risk was observed in subjects presenting 
with a high birth weight (>4000 g) relative to subjects with an intermediate 
birth weight of 3000-4000 g (Study I). In particular, schizophrenia risk was 
elevated among high birth weight individuals in combination with specific 
variants of the NDE1 gene (Study IV). Both low and high birth weight were 
found to be associated with increased severity of disorganized and negative 
symptom dimensions, whereas birth weight was not associated with 
symptoms of reality distortion (Study II). Both low and high birth weight, 
compared with the intermediate birth weight range, were associated with a 
slight decrease in cognitive performance among both subjects with 
schizophrenia and their unaffected first-degree relatives (Study III).  
The observations in the thesis corroborate existing findings describing an 
association between high birth weight and increased schizophrenia risk. An 
association between low birth weight and increased schizophrenia risk, a 
finding widely documented in the literature, was not seen here. Birth weight 
was found to influence both symptom severity and cognitive performance in 
schizophrenia. The findings also suggest that the functions of NDE1 during the 
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early stages of neurodevelopment are vulnerable to the influence of pre- and 
perinatal environmental factors associated with high birth weight, with the 
propensity to augment subsequent schizophrenia susceptibility among 
offspring. The mechanisms underlying the association between high birth 
weight and schizophrenia risk are speculative, but may involve factors such as 
pre- or perinatal hypoxia, maternal metabolic and immunological 
mechanisms during pregnancy. 
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TIIVISTELMÄ(
Raskauden- ja synnytyksenaikaisten komplikaatioiden on todettu lisäävän 
skitsofreniaan sairastumisen riskiä, etenkin geneettiseen alttiuteen 
yhdistettynä. Sekä alhainen että suuri syntymäpaino on todettu yhdistyvän 
kohonneeseen riskiin sairastua skitsofreniaan ja myös autismiryhmän 
häiriöihin. Tiettyjen skitsofrenialle altistavien geenien on todettu lisäävän 
skitsofrenia alttiutta sikiö- ja synnytyksenaikaisiin komplikaatioihin 
yhdistettynä.  
Tässä väitöskirjatyössä tutkittiin syntymäpainon yhteyttä skitsofreniariskiin 
(osajulkaisu I), psykoosioireiden vaikeusasteeseen (osajulkaisu II), ja 
kognitiiviseen suorituskykyyn (osajulkaisu III) osana ”Vakavien 
mielenterveyshäiriöiden geneettinen epidemiologia ja molekyyligeneettinen 
perusta” –projektia varten kerätyssä perheaineistossa, jossa skitsofrenian 
geneettisen alttiuden tiedetään olevan muuta väestöä suurempi. Aineisto 
koostui kahdesta osa-aineistosta, joissa kussakin perheyksikössä oli vähintään 
yksi skitsofreniaan sairastunut jälkeläinen. Työssä tutkittiin myös tiettyjen 
DISC1 -polun geenien ja syntymäpainon yhteisvaikutuksia skitsofrenia-
alttiuteen (osajulkaisu IV). Analyyseissä tarkastelun kohteena olevien DISC1-
polun geeni varianttien on aikaisemmissa tutkimuksissa osoitettu lisäävän 
skitsofreniariskiä samassa perheaineistossa. 
Skitsofreniariskin havaittiin olevan 1.68-kertaisesti suurempi yksilöillä, joiden 
syntymäpaino oli suuri (>4000 g), verrattuna yksilöihin, joiden syntymäpaino 
oli 3000 g – 4000 g (osajulkaisu I). Skitsofrenia-alttiuden havaittiin olevan 
korkeampi eteenkin niiden yksilöiden joukossa, jotka kantoivat NDE1 geenin 
tiettyjä variantteja ja joilla oli suuri syntymäpaino (osajulkaisu IV). Sekä 
alhaisen että suuren syntymäpainon havaittiin yhdistyvän hajanaisten ja 
negatiivisten oireiden vaikeusasteeseen, kun taas syntymäpainolla ei todettu 
olevan yhteyttä aistiharhojen ja harhaluulojen vaikeusasteeseen (osajulkaisu 
II). Sekä alhaisen että suuren syntymäpainon havaittiin yhdistyvän alempaan 
kognitiiviseen suorituskykyyn sekä skitsofreniapotilailla ja heidän 
ensimmäisen asteen sukulaisilla (osajulkaisu III).  
Tämän väitöskirjatyön havainnot tukevat aikaisempia havaintoja siitä, että 
suuri syntymäpaino saattaa lisätä skitsofreniaan sairastumisen 
todennäköisyyttä. Toisin kuin aikaisemmissa tutkimuksissa alhainen 
syntymäpaino ei lisännyt sairastumisriskiä. Tutkimuksen havainnot tukevat 
myös käsitystä siitä, että NDE1-geenin toiminta keskushermoston 
kehityksessä on altis syntymäpainoon liittyvien raskauden- ja 
synnytyksenaikaisten komplikaatioiden vaikutukselle. Havaintojen taustalla 
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olevat patofysiologiset mekanismit jäävät todentamatta, mutta niiden 
arvioidaan mahdollisesti liittyvän sikiön raskauden- tai synnytyksenaikaiseen 
hapenpuutteeseen, äidin raskaudenaikaisiin metabolisiin tai immunologisiin 
tekijöihin.  
8 
ACKNOWLEDGEMENTS(
This study was conducted at the Mental Health Unit of the National Institute 
for Health and Welfare (THL), formerly the National Public Health Institute 
(KTL), in 2008-2016. I wish to thank Professor Juhani Eskola and Professor 
Pekka Puska, who have been the Director Generals of THL during this work, 
for providing such a great place to do research. I sincerely thank the former 
and the current Heads of the Mental Health Unit, Professor Jouko Lönnqvist, 
Professor Mauri Marttunen and Professor Jaana Suvisaari, for providing such 
excellent research facilities. Professor Antti Mäkitie, Head of the Doctoral 
Program in Clinical Research, I thank for the opportunity to study in the 
graduate school.  
I warmly thank all patients and their families for participating in the study.  
My deepest gratitude is owed to my supervisors for their commitment and 
support throughout this process. I am very grateful to Professor Tiina Paunio 
for her pragmatic and constructive comments every step of the way. Her vision 
and encouragement have propelled my thesis forward, especially during the 
times when momentum was required. I am indebted to Professor Jaana 
Suvisaari for her exceptional vision, dedication and continuing guidance 
throughout the making of this thesis. The level of commitment and support 
that I received from Jaana is immense; this together with her empathetic 
nature form a combination of qualities that I have never before encountered 
to such a high degree in any professional setting during the course of my 
career. I can honestly say that it has been honour to have had you as my 
supervisor. I also extend my gratitude to Professor Annamari Tuulio-
Henriksson for her active and constructive role during the initial part of the 
project. I especially thank her for the enjoyable discussions on matters related 
to cognition. 
I owe a debt of gratitude to both the late Professor Leena Peltonen-Palotie and 
Professor Jouko Lönnqvist for their central roles in the establishment of the 
Finnish schizophrenia family study sample. I am very grateful to have had the 
opportunity to collaborate with Professor Jouko Lönnqvist during this project. 
His vision and enthusiasm towards the field of psychiatry are truly inspiring. 
He is a formidable and highly respected figure in psychiatry, both nationally 
and internationally, yet he is exceedingly gracious and respectful with all of his 
colleagues irrespective of their level of proficiency. I am also very grateful to 
have had the opportunity to meet the late Professor Peltonen-Palotie during 
the initial phase of the project. Her spirit and dedication towards research live 
on in those with whom she came into contact.  
 9 
I am grateful to have collaborated with Docent William Hennah. Thank you 
Will for numerous insightful discussions on the genetics of neurodevelopment. 
These conversations have been most inspiring and motivating.  
Maiju Pankakoski, I warmly thank for statistical expertise during the course of 
this project. Maiju was always patient and took the time to explain in detail 
topics related to statistics. This thesis would not have been written without 
your huge contribution.  
I warmly thank Minna Torniainen-Holm, the first author of the third article, 
for numerous fruitful discussions on statistics and cognition. I also thank 
Marjut Grainger for her active role in the management of data.  
This thesis has been written in a fairly solitary fashion, in parallel with my 
ongoing clinical work. I warmly thank my other co-authors for their valuable 
contributions: Docent Jaana Suokas, Docent Jari Haukka, Ulriika Lehto, 
Laura Häkkinen, and Liisa Tomppo. I am also grateful to all fellow researchers 
at THL, especially those whom I have had the opportunity to discuss matters 
related to the project: Laura Auvinen-Lintunen, Teija Kasteenpohja, Nina 
Markkula and Satu Viertiö. Thank you both Niina and Laura for supportive 
discussions that motivated me to complete this thesis.  
I thank all those who participated in the collection of the Finnish 
schizophrenia study sample, particularly Professor Jesper Ekelund and Ritva 
Arajärvi, with whom I had the good fortune to have discussed matters related 
to the study sample.  
I am sincerely grateful to the reviewers of this thesis, Professor Soili Lehto and 
Professor Christina Dalman, for their constructive comments and valuable 
suggestions. The manuscript has been greatly improved by these comments. I 
also warmly thank Professor Jyrki Korkeila for accepting the role of Opponent 
and Professor Tiina Paunio for accepting the role of Custos in the defence of 
my thesis.  
Carol Ann Pelli is thanked for editing the language of this manuscript. 
I thank my former and current superiors and former clinical supervisors 
during my years in HUS Psychiatry. Docent Matti Holi, Docent Tuula 
Kieseppä, Docent Samuli Saarni, Docent Tanja Svirskis and Docent Kaisla 
Joutsenniemi I thank for being very supportive of research in HUS. Matti Holi 
and Tuula Kieseppä have been my long-standing supervisors during my 
training at Peijas Hospital, and I warmly thank them for their support, 
mentorship and enthusiasm towards the field of psychiatry, which have greatly 
influenced the way I view and practice psychiatry today. I also thank all my 
colleagues at HUS Psychiatry with whom I have had the good fortune to work 
10 
and discuss matters related to clinical psychiatry with: Kristiina Golan, 
Anniina Koski, Max Franzén, Anne Meriluoto, Marcelo Chiramberro, Maxim 
Shein, Elena Chukhina, Evgeny Chukhin, Juhana Santti, Jorma Oksanen, 
Allan Seppänen, Docent Katinka Tuisku, Docent Pekka Tani and Professor 
Nina Lindberg.  
I warmly thank all of my friends, many of whom I have known since 
elementary school. I am especially grateful to Niko, Janne and Mathew for 
many enjoyable moments and laughs over the years.   
Last, but not least, I thank my parents, Sakari and Marita, for providing me 
with the tools needed to lead an enjoyable and fulfilling life. My mother I thank 
for giving me a strong sense of empathy. My father I thank for his energetic 
and pragmatic approach to life, teaching me to be forever active and inquisitive 
about the world around me and also to appreciate the small everyday things in 
life, which can so easily be taken for granted. My brothers, Vesa and Juha, I 
thank for brotherly support manifesting as time spent together at the cinema, 
ice hockey matches and enjoying big steaks.  
Without a doubt, the greatest support group has been by family. Thank you 
Marika for this ongoing journey and for all that we have shared. Thank you for 
always encouraging me to do what I feel is right, even if this has sometimes 
resulted in a bumpier road for you. I cannot comprehend my life without you. 
Mikael and Emilia, thank you for always being so happy to see me as soon as I 
walk in the door. Thank you for making every day fun and special. The future 
is so bright for both of you.  
Financial support from the Academy of Finland, the Sigrid Juselius 
Foundation, the Finnish Medical Foundation, the Finnish Foundation for 
Psychiatric Research and the Jalmari and Rauha Ahokas Foundation is 
gratefully acknowledged. 
 
 
 
 
 
 
 
 
 
 
Asko Wegelius 
Helsinki, March 2017 
 11 
CONTENTS(
ABSTRACT'......................................................................................................'IV'
TIIVISTELMÄ'...................................................................................................'VI'
ACKNOWLEDGEMENTS'................................................................................'VIII'
LIST'OF'ORIGINAL'PUBLICATIONS'..................................................................'13'
ABBREVIATIONS'............................................................................................'14'
1.'INTRODUCTION'.........................................................................................'16'
2.'REVIEW'OF'THE'LITERATURE'.....................................................................'18'
!!!2.1.!HISTORICAL!PERSPECTIVE!..........................................................................!18!
!!!2.2.!DIAGNOSIS!OF!SCHIZOPHRENIA!.................................................................!19!
!!!2.3.!SYMPTOMS!OF!SCHIZOPHRENIA!................................................................!23!
!!!!!!2.3.1.!POSITIVE!SYMPTOMS!...........................................................................!23!
!!!!!!2.3.2.!NEGATIVE!SYMPTOMS!.........................................................................!26!
!!!2.4.!COGNITIVE!IMPAIRMENT!IN!SCHIZOPHRENIA!...........................................!28!
!!!2.5.!EARLY!PHASES!OF!SCHIZOPHRENIA!...........................................................!30!
!!!2.6.!AETIOLOGICAL!MODELS!OF!SCHIZOPHRENIA!............................................!31!
!!!2.7.!RISK!FACTORS!.............................................................................................!33!
!!!!!!2.7.1.!GENETIC!RISK!FACTORS!........................................................................!33!
!!!!!!2.7.2.!ENVIRONMETAL!RISK!FACTORS.!...........................................................!41!
!!!!!!!!!2.7.2.1.!PREA!AND!PERINATAL!RISK!FACTORS.!.............................................!41!
!!!!!!!!!2.7.2.2.!POSTNATAL!RISK!FACTORS.!............................................................!54!
!!!!!!2.7.3.!GENEAENVIRONMENT!INTERACTIONS!..................................................!56!
!!!!!!!!!2.7.3.1.!PREA!AND!PERINATAL!PERIODS!.......................................................!56!
!!!!!!!!!2.7.3.2.!POSTNATALAPREMORBID!PERIOD!...................................................!59!
!!!2.8.!TREATMENT!OF!SCHZIOPHRENIA!...............................................................!63!
3.'AIMS'OF'THE'STUDY'..................................................................................'64'
4.'METHODS'.................................................................................................'65'
!!!4.1.!THE!FINNISH!SCHIZOPHRENIA!FAMILY!STUDY!SAMPLE!.............................!65!
12 
!!!!!!4.1.2!PARTICIPANTS!.......................................................................................!69!
!!!4.2.!BIRTH!WEIGHT!DATA!.................................................................................!72!
!!!4.3.!NEUROPSYCHOLOGICAL!MEASURES!..........................................................!72!
!!!4.4.!GENOTYPES!................................................................................................!73!
!!!4.5.!STATISTICAL!ANALYSIS!...............................................................................!74!
5.'RESULTS'....................................................................................................'76'
!!!5.1.!BIRTH!WEIGHT!AND!SCHIZOPHRENIA!RISK!................................................!76!
!!!5.2.!BIRTH!WEIGHT!AND!SYMPTOM!SEVERITY!.................................................!77!
!!!5.3.!BIRTH!WEIGHT!AND!COGNITIVE!IMPAIRMENT!..........................................!78!
!!!5.4.!INTERACTION!OF!BIRTH!WEIGHT!AND!GENES!OF!THE!DISC1!NETWORK!...!79!
6.'DISCUSSION'..............................................................................................'81'
!!!6.1.!BIRTH!WEIGHT!AND!SCHIZOPHRENIA!RISK!................................................!81!
!!!6.2.!BIRTH!WEIGHT!AND!SYMPTOM!SEVERITY!.................................................!84!
!!!6.3.!BIRTH!WEIGHT!AND!COGNITIVE!IMPAIRMENT!..........................................!86!
!!!6.4.!INTERACTION!BETWEEN!HBW!AND!NDE1!.................................................!87!
!!!6.5.!STRENGTHS!AND!LIMITATIONS!OF!THE!STUDY!..........................................!89!
7.'CONCLUSIONS'...........................................................................................'90'
8.'FUTURE'AREAS'OF'INVESTIGATION'...........................................................'93'
9.'REFERENCES'..............................................................................................'96'
'
 
 
 13 
LIST(OF(ORIGINAL(PUBLICATIONS(
This thesis is based on the following publications: 
 
I.! Wegelius, A., Tuulio-Henriksson, A., Pankakoski, M., Haukka, J., Lehto, 
U., Paunio, T., Lönnqvist, J., Suvisaari, J. (2011). An association between 
high birth weight and schizophrenia in a Finnish schizophrenia family 
study sample. Psychiatry Res. 190 (2-3) 181-186.  
II.! Wegelius, A., Pankakoski, M., Lehto, U., Suokas, J., Häkkinen, L., Tuulio-
Henriksson, A., Lönnqvist, J., Paunio, T., Suvisaari, J., (2012). An 
association between both low and high birth weight and increased 
disorganized and negative symptom severity in schizophrenia and other 
psychoses. Psychiatry Res. 205 (1-2) 18-24. 
III.! Torniainen, M., Wegelius, A., Tuulio-Henriksson, A., Lönnqvist, J., 
Suvisaari, J. (2013). Both low birthweight and high birthweight are 
associated with cognitive impairment in persons with schizophrenia and 
their first-degree relatives. Psychol. Med. 43(11) 2361-2367. 
IV.! Wegelius, A., Pankakoski, M., Tomppo, L., Lehto, U., Lönnqvist, J., 
Suvisaari, J., Paunio, T., Hennah W. (2015) An Interaction Between 
NDE1 and High Birth Weight Increases Schizophrenia Susceptibility. 
Psychiatry Res. 230(2) 194-199. 
 
 
The publications are referred to in the text by their Roman numerals. They are 
reprinted with the permission of their copyright holders. In addition, some 
unpublished material is presented. 
 
 
 14 
ABBREVIATIONS (
AKT1  Serine-Threonine Protein Kinase 
APP  Amyloid Precursor Protein  
ASD Autism Spectrum Disorder 
BDNF  Brain-Derived Neurotrophic Factor 
cAMP  Cyclic Adenosine Monophosphate  
CHRNA7  Cholinergic Receptor Nicotinic Alpha 7 Subunit 
CMV Cytomemalovirus 
CNR1  Cannabinoid Receptor 1 
CNS  Central Nervous System  
CNV Copy Number Variant  
COMT Catecholamine-O-Methyl-Transferase  
DAT1  Dopamine Transporter 1 
DISC  Disrupted in Schizophrenia  
DIXDC1 DIX domain containing 1  
DRD2 D2-Dopamine Receptor 
DRD4  D4-Dopamine Receptor 
DSM Diagnostic and Statistical Manual of Mental Disorders  
DTNBP1  Dystrobrevin Binding Protein 1 
FEZ1  Fasciculation and Elongation Protein Zeta 1  
FK506  FK506 Binding Protein 
FOXP2  Forkhead Box P2  
FTD Formal Thought Disorder  
GAF  Global Assessment of Functioning  
GEE General Estimating Equation  
GSK3β   Glycogen Synthase Kinase 3 Beta  
GRIN Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate  
GRM  Glutamate Metabotropic Receptor  
GWAS Genome-Wide Association Study 
HBW High Birth Weight 
HLA  Human Leukocyte Antigen 
HRR Hazard Rate Ratio 
HSV Herpes Simplex Virus 
HTTLPR  Serotonin-transporter-linked polymorphic region  
ICD International Classification of Diseases 
IGF  Insulin-like factor 
IRR Incidence Rate Ratio 
LBW Low Birth Weight 
LD  Linkage disequilibrium  
LIS1 Lissencephaly-1  
 15 
MATRICS Measurement and Treatment Research to Improve Cognition in 
Schizophrenia 
MET Methionine 
MTHFR  Methylenetetrahydrofolate Reductase 
NDE1 Nuclear Distribution Factor E  
NDEL1 Nuclear Distribution Factor E-like Factor  
NFBC Northern Finland 1966 Birth Cohort  
NICE National Institute of Health and Care Excellence 
NMDA  N-Methyl-D-Aspartate 
NOSA1P  Nitric Oxide Synthase 1 [Neuronal] Adaptor Protein  
NOTCH4  Neurogenic Locus Notch Homologue 
NRG1  Neuregulin 1 
OR Odds Ratio 
PANSS  Positive and Negative Syndrome Scale 
PDE Phosphodiesterase  
PIS  Population Information System  
PPD Primary Psychotic Disorder 
PRODH  Proline Dehydrogenase 
SANS Scale for Assessment of Negative Symptoms   
SAPS Scale for Assessment of Positive Symptoms 
SNP Single-Nucleotide Polymorphism  
SNV Single-Nucleotide Variation  
SSD Schizophrenia Spectrum Disorder  
ST8SIA2  ST8 Alpha-N-acetyl-Neuraminide Alpha-2,8-Sialyltransferase 2  
T2DM Type II Diabetes Mellitus 
TNF  Tumour Necrosis Factor  
TRAK1 Trafficking Kinesin Protein 1 
RGS4  Regulator of G-Protein Signalling 4 
ROS Reactive oxygen species 
TPH  Tryptophan Hydroxylase 
VAL Valine 
VLBW          Very low birth weight  
ZEB1  Zinc Finger E-Box Binding Homeobox 1 
 
 
 16 
1.INTRODUCTION(
Accumulating evidence suggests that the aetiology of schizophrenia is 
multifactorial, involving the interaction of genetic risk variations and 
environmental factors, and its pathogenesis has been proposed to originate 
long before the onset of psychotic symptoms (Lichtenstein et al., 2009; Insel, 
2010; Van Os et al., 2010; Dick, 2011; Sullivan et al., 2012). Although psychotic 
symptoms are central to the diagnosis of schizophrenia, cognitive impairment 
and negative symptom severity dictate outcome-related measures (Karow et 
al., 2014; Kirkpatrick, 2014). Many schizophrenia-associated risk factors have 
been characterized, but less is known about the impact of these risk factors on 
symptom severity and clinical presentation of the disorder.   
 
Pre- and perinatal factors represent a widely replicated group of 
environmental factors associated with schizophrenia risk (Cannon et al., 
2002a; Byrne et al., 2007; Rapoport et al., 2012). The association between low 
birth weight (LBW) and schizophrenia is a consistent finding in the literature 
(Cannon et al., 2002a; Abel et al., 2010; Byars et al., 2014). Birth weight has 
been speculated to represent a proxy variable reflecting the influence of 
various environmental factors acting on the developing foetus (Fineberg et al., 
2013; Galjaard et al., 2013; O'Connor et al., 2013). Evidence has suggested that 
high birth weight (HBW) may also increase schizophrenia risk (Hultman et al., 
1997; Gunnell et al., 2003; Bersani et al., 2007; Moilanen et al., 2010; 
Keskinen et al., 2013).  
 
A recent genome-wide association study (GWAS) has supported previous 
findings implicating a role for genes involved in immunological functioning, 
dopaminergic and glutamatergic neutrotransmission, calcium signalling, cell 
adhesion, neuronal plasticity, and neurotransmitter release in schizophrenia-
associated pathogenesis (Schizophrenia Genomics Consortium, 2014). 
 
Genes of the Disrupted in Schizophrenia 1 (DISC1) network have been 
established to be associated with neurodevelopment (Devine et al., 2016). An 
association between schizophrenia and variants of DISC1, as well as other 
DISC1-associated gene variants, including nuclear distribution factor E 
(NDE1), nuclear distribution factor E-like factor (NDEL1), phosphodiesterase 
4B (PDE4B) and phosphodiesterase 4D (PDE4D), have been found in the 
Finnish schizophrenia family sample (Ekelund et al., 2001; Hennah et al., 
2003; Hennah et al., 2004; Hennah et al., 2007; Tomppo et al., 2009). 
Evidence suggests that DISC1 may also be associated with intermediate 
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neurocognitive phenotypes in schizophrenia and other psychiatric disorders 
(Hennah et al., 2005; Carless et al., 2011). 
 
The aim of this thesis was to investigate the relationship between birth weight 
and both schizophrenia risk and the clinical presentation of schizophrenia, 
with respect to symptom severity and cognitive functioning, in a Finnish 
schizophrenia family study sample with high genetic loading for schizophrenia 
(Hovatta et al., 1997; Hovatta et al., 1999; Ekelund et al., 2000; Paunio et al., 
2001). The interaction between birth weight and genetic variants from the 
DISC1 network (Hennah et al., 2007) was also evaluated.  
 
It was hypothesized that the association between birth weight and 
schizophrenia risk would be augmented in a cohort presenting with increased 
genetic loading for schizophrenia. It was also hypothesized that deviations of 
birth weight may influence symptom severity and cognitive functioning in 
schizophrenia. Genes of the DISC1 network were postulated to interact with 
birth weight in augmenting schizophrenia risk.  
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2.( REVIEW(OF(THE(LITERATURE(
Schizophrenia is one of the most severe psychiatric disorders, characterized by 
pronouced disturbances in fundamental processes governing human 
behaviour (Insel, 2010). The disorder typically manifests with marked social 
and occupational impairment and reduced life expectancy (McEvoy et al., 
2005; Lauronen et al., 2007; Perälä et al., 2007; Saha et al., 2007; Kiviniemi 
et al., 2010; Wildgust et al., 2010; Laursen et al., 2012; Viertiö et al., 2012; 
Crump et al., 2013; Nordentoft et al., 2013; Suvisaari et al., 2013; Ringen et 
al., 2014). In addition to elevated morbidity, the financial burden of 
schizophrenia on society is formidable (Gustavsson et al., 2011).  
2.1.( HISTORICAL(PERSPECTIVE(
In the late nineteenth century, the German psychiatrist Emil Kraepelin 
introduced the term Dementia praecox to describe a form of premature 
dementia that (1) had an onset in late adolescence and (2) was proposed to 
have a deteriorating course. Kraepelin described Dementia praecox as a 
disorder distinct from the remitting and non-deteriorating course seen in 
individuals presenting with manic-depressive illness (Insel, 2010).  
 
The term schizophrenia was introduced in 1908 by the Swiss psychiatrist 
Eugen Bleuler, who emphasized the construct as being highly heterogeneous 
with respect to both clinical presentation and prognosis, as echoed by Bleuler’s 
use of the term “a group of schizophrenias” (Insel, 2010). Bleuler’s focus was 
on delineating a core unifying symptom underlying the disorder, which he 
concluded as being “the breaking up or splitting of psychic functioning”. 
Bleuler described the terms Affect, Autism, loosening of Associations, 
Ambivalence and deficits in Attention to describe core manifestations of 
schizophrenia (Bleuler, 1911, translated by Zinkin, 1950; Kuhn, 2004; Hahn et 
al., 2012). Bleuler’s description of the disorder and use of the Greek term 
phrene – mind – has been suggested to emphasize impaired cognition as a 
defining core feature of the original definition of schizophrenia (Andreasen, 
1999).  
The diagnosis of schizophrenia was refined by the German psychiatrist Kurt 
Schneider, who set out to differentiate schizophrenia from other psychotic 
disorders by attempting to describe symptoms specific to schizophrenia 
(Cutting, 2015). Schneider’s eleven first rank symptoms audible thoughts, 
voices arguing and/or discussing, voices commenting, somatic passivity 
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experiences, thought withdrawal, thought insertion, thought broadcasting, 
made volition, made affect, made impulse and delusional perception have 
remained central to the diagnostic criteria of schizophrenia (Carpenter, 1974; 
Nordgaard et al., 2008; Tandon et al., 2013; American Psychiatric Association, 
2014). Schneider emphasized these symptoms of reality distortion as being 
pathognomic to schizophrenia, which has been suggested to have led to a 
relative neglect in the development of treatments for other core symptoms 
underlying the disorder (Carpenter et al., 2004). 
2.2.( DIAGNOSIS(OF(SCHIZOPHRENIA(
Despite recent advances in the fields of genetics and brain imaging, the 
diagnosis of schizophrenia is still purely descriptive, based on clinical 
observation and patient interviews (World Health Organization, 1993; 
American Psychiatric Association, 2014). Kraeplin, Bleuler and Schneider’s 
conceptualization of schizophrenia reflect the roots of today’s diagnostic 
classification of schizophrenia (Tandon et al., 2013). The diagnostic criteria of 
schizophrenia with respect to the International Classification of Diseases, 
tenth revision (ICD-10) (World Health Organization, 1993), the Diagnostic 
and Statistical Manual of Mental Disorders, fourth edition, text revision 
(DSM-IV) (American Psychiatric Association, 2000) and the Diagnostic and 
Statistical Manual of Mental Disorders, fifth edition (DSM-5) (American 
Psychiatric Association, 2014) are presented in Tables 1, 2 and 3, respectively.  
 
DSM-IV includes the criterion that symptoms must result in functional 
impairment. ICD-10 does not include a criterion of functional impairment. 
DSM-IV also requires that continuous signs of the disturbance in some form 
have persisted for a period of at least 6 months, in comparison to ICD-10, 
which requires that symptoms have been present for one month. Both the ICD-
10 and DSM-IV differentiate between different subtypes of schizophrenia.  
 
In DSM-5 (American Psychiatric Association, 2014), the diagnosis of 
schizophrenia has been further refined relative to DSM-IV. In DSM-5, the 
special emphasis on Schneiderian first-rank symptoms has been eliminated. 
In DSM-5 two or more of the following symptoms must be present for a 
significant proportion of time over a one-month period: delusions, 
hallucinations, disorganized speech, grossly disorganized or catatonic 
behaviour and negative symptoms, and one of the symptoms must be 
delusions, hallucinations or disorganized speech (Tandon et al., 2013). DSM-
5 no longer distinguishes different subtypes of schizophrenia, and catatonia 
can be used as a descriptive specifier to describe the phenotype of any 
psychiatric disorder. 
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Table(1.( ICDO10!diagnostic!criteria!of!schizophrenia.!!
 
 
 
 
 
 
 
 
 
G1.1!Either at(
least one of!the!
syndromes,!
symptoms!and!
signs!A1OA4!
should!be!
present!for!most!
of!the!time!for!at(
least(one(month.
A1.!Thought!echo, thought!insertion,!thought!withdrawal, thought!
broadcasting.
A2.!Delusions!of!control,!influence!or!passivity,!clearly!referring!to!body!or!
limb!movements!or!specific!thoughts,!actions!or!sensationsT!delusional!
perception.
A3.!Hallucinatory!voices!giving!a!running!commentary!on!the!patient's!
behaviour,!or!discussing!him!between!themselves,!or!other!types!of!
hallucinatory!voices!coming!from!some!part!of!the!body.
A4.!Persistent!delusions!of!other!kinds!that!are!culturally!inappropriate!
and!completely!impossible!
G1.2 Or at(least(
two of the(
syndromes,!
symptoms!and!
signs!B1OB4!
should!be!
present!for!most!
of!the!time!for!at(
least(one(month.
B1.!Persistent!hallucinations!in!any!modality,!when!accompanied!by!
delusions,!without!clear!affective!content,!or!when!accompanied!by!
persistent!overOvalued ideas.
B2.!Neologisms,!breaks!or!interpolations!in!the!train!of!thought,!resulting!
in!incoherence!or!irrelevant!speech.
B3.!Catatonic!behaviour,!such!as!excitement,!posturing!or!waxy!flexibility,!
negativism,!mutism!and!stupor.
B4.!Negative!symptoms!such!as!marked!apathy,!paucity!of!speech!and!
blunting!or!incongruity!of!emotional!responses.!
G2.!Most!
commonly!used!
exclusion!criteria:!
If!the!patient!also!meets!criteria!for!manic!episode!(F30)!or!depressive!
episode!(F32),!the!criteria!listed!under!G1.1!and!G1.2!above!must!have!
been!met!before!the!disturbance!of!mood!developed.!
The!disorder!is!not!attributable!to!organic!brain!disease!(F0X)!or!to!
alcoholO or!drugOrelated!intoxication,!dependence!or!withdrawal.
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Table(2.( DSMOIV!diagnostic!criteria!of!schizophrenia.!
 
 
A.!Two!(or!more)!
of!the!symtoms!
A1OA5,!are!
present!for!a!
significant!portion!
of!time!during!a!
6Omonth!period!
(or!less!if!
successfully!
treated)!
(A1)!Delusion
(A2)!Hallucinations
(A3)!Disorganized!speech
(A4)!Grossly!disorganized!or!catatonic!behaviour
(A5)!Negative!symptoms
Only!one!Criterion!is!required!if!delusions!are!bizarre!or!hallucinations!
consist!of:
(I)!a!voice!keeping!up!a!running!commentary!on!the!person's!behaviour!
or!thoughts,!or
(II)!two!or!more!voices!conversing!with!each!other.
B.!Social!/!
occupational!
dysfunction
For a significant portion of the time since the onset of the disturbance,
one or more major areas of functioning such as work, interpersonal
relations or selfOcare are markedly below the level achieved prior to the
onset (or when the onset is in childhood or adolescence, failure to
achieve an expected level of interpersonal, academic or occupational
achievement).
C. Duration Continuous signs of the disturbance persist for at least 6 months. This 6O
month period must include at least one month of symptoms (or less if
successfully treated) that meet Criterion A (i.e., activeOphase symptoms)
and may include periods of prodromal or residual symptoms.
During these prodromal or residual periods, the signs of the disturbance
may be manifested by only negative symptoms or two or more symptoms
listed in Criterion A present in an attenuated form.
D.!
Schizoaffective!
and!Mood!
Disorder!
exclusion
Schizoaffective Disorder aand Mood Disorder With Psychotic Features
have been ruled out because either:
(1) no Major Depressive Episode, Manic Episode or Mixed Episode have
occurred concurrently with the activeOphase symptomsT or
(2) if mood episodes have occurred during activeOphase symptoms, their
total duration has been brief relative to the duration of the active and
residual periods.
E.!Substance!
/general!medical!
condition!
exclusion
The disturbance is not due to the direct physiological effects of a
substance or a general medical condition.
F.!Relationship!to!
a!Pervasive!
Developmental!
Disorder
If there is a history of Autistic Disorder or another Pervasive
Developmental Disorder, the additional diagnosis of Schizophrenia is
made only if prominent delusions or hallucinations are also present for at
least one month (or less if successfully treated).
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Table(3.( DSMO5!diagnostic!criteria!of!schizophrenia.!
!
A.!Two!(or!more)!of!the!
following!symptoms.!Each!
present!for!a!portion!of!time!
during!a!oneOmonth!period!(or!
less!if!successfully!treated).!At!
least!one!of!these!must!be!
(A1),!(A2)!or!(A3).
(A1)!Delusions
(A2) Hallucinations!
(A3) Disorganized!speech!
(A4) Disorganized!behaviour!or!catatonic!behaviour
(A5)!Negative!symptoms
B.!For!a!significant!portion!of!
time!since!the!onset!of!the!
distrubance!the!level!of!
functioning!in!one!or!more!
major!areas!of!the!following!is!
markedly!below!the!level!
achieved!prior!to!the!onset:
Work, interpersonal relations, selfOcare.
Or when the onset is in childhood or adolescence, there is
failure to achieve expected level of interpersonal, academic,
occupational functioning.
C.!Continuous!signs!of!the!
distubance!persist!for!at!least!
6!monsts.!This!6Omonth!period!
must!include!at!least!one!
month!of!symptoms!(less!if!
successfully!treated)!that!meet!
Criterion!A
ActiveOphase symptoms may include periods of prodromal
symptoms
Residual symptoms. During these prodromal or residual
period the signs of the disturbance may be manifested by
only negative symptoms or by two or more symptoms listed
in Criterion A present in an attenuated form, e.g. odd beliefs,
unusual perceptual experiences).
D.!Schizoaffective!disorder,!!
depressive!or!bipolar!disorder!
with!psychotic!featurs!have!
been!ruled!out!because!either
(1) No major depressive or manic episodes has occurred
concurrently with activeOphase symptoms.
(2) Or they have been present for a minority of the total
duration of the active and residual periods of the illness.
E.The!disturbance!is!not!
attributable!to!the!physiological!
effects!of!a!substance
A drug of abuse, a medication or a medical condition.
F.!If!there!is!a!history!of!autism!
spectrum!disorder!or!a!
communucation!disorder!of!
childhood!onset.
The additional diagnosis of schizophrenia is made only if
prominent delusions or hallucinations, in addition to other
required symptoms of schizophrenia, are also present for at
least one month.
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2.3.( SYMPTOMS(OF(SCHIZOPHRENIA(
Although the diagnosis of schizophrenia is categorical, psychotic symptoms in 
the general population have been suggested to reflect a dimensional 
continuum (Linscott and Van Os, 2010). The schizophrenia phenotype has 
been suggested to reflect an extreme phenotype of this continuum (Van Os et 
al., 2010). Dissection of the schizophrenia phenotype into clinically relevant 
symptom dimensions has been proposed to both facilitate our understanding 
of the aetiological mechanisms underlying the disorder and increase the 
efficacy of treatments targeting specific symptom dimensions (Derks et al., 
2010; Wykes et al., 2011). 
 
Symptoms have broadly been found to cluster into two clearly discernible 
domains, historically referred to as positive and negative symptoms 
(Andreasen et al., 1995). Positive symptoms have been suggested to reflect a 
state presenting with “an excess of vital properties” (the presence of something 
that should be absent), and negative symptoms reflecting “the loss of vital 
properties” (the absence of something that should be present) (Andreasen, 
1995; Messinger et al., 2011).  
 
Structured symptom rating scales have been developed to aid goal-directed 
treatment of psychotic disorders. Commonly used scales include (1) the Scale 
for Assessment of Positive Symptoms (SAPS) (Andreasen, 1984), (2) the Scale 
for Assessment of Negative Symptoms (SANS) (Andreasen, 1983), (3) the 
Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987), (4) the Brief 
Psychiatric Rating Scale (Overall and Gorham, 1962). The clinical reliability 
and validity of symptom rating scales is well established (Klimidis et al., 1993; 
Andreasen et al., 1995). 
 
 
 
2.3.1.( POSITIVE(SYMPTOMS(
((
Positive symptoms are longitudinally more fluctuating than negative 
symptoms, which are more stable and enduring (Andreasen et al., 1995; 
Kirkpatrick et al., 2006; Kirkpatrick, 2014; Austin et al., 2015) (Table 4).  
Positive symptoms in psychotic disorders segregate into two clinically 
distinguishable domains: (1) symptoms of reality distortion and (2) 
disorganized symptoms, which differ with respect to clinical presentation, 
symptom stability and outcome measures (Ventura et al., 2010). Symptoms of 
reality distortion consist of (1) delusions and (2) hallucinations (Andreasen, 
1986). Disorganized symptoms are typically divided into (1) disorganized 
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thought, referring to the terms conceptual disorganization and positive formal 
thought disorder and (2) disorganized behaviour (Ventura et al., 2010) (Figure 
1).  
Disorganized symptoms have been found to be associated with greater 
cognitive impairment (Ventura et al., 2010; Ventura et al., 2013; Minor and 
Lysaker, 2014) and greater impairment in long-term functioning than 
symptoms of reality distortion (Ventura et al., 2010). Formal thought disorder 
has been found to moderate the relationship between neurocognition, social 
cognition and metacognition, suggesting that the presence of disorganized 
symptoms in schizophrenia limits the effective utilization of the 
neurocognitive abilities necessary for performing social cognitive or 
metacognitive tasks (Minor and Lysaker, 2014; Minor et al., 2015).  
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2.3.2.( NEGATIVE(SYMPTOMS((
(
In the 1970s and 1980s, negative symptoms were described as being separable 
from other symptoms of schizophrenia (Carpenter et al., 1988; Strauss et al., 
2013). Negative symptoms are divided into primary and secondary negative 
symptoms with respect to aetiological considerations (Carpenter et al., 1988; 
Kirkpatrick, 2014). Primary negative symptoms, also referred to as deficit 
symptoms, are suggested to be more proximal to the biological core of the 
disorder and are associated with increased cognitive, social and functional 
impairment (Kirkpatrick, 2014). Secondary negative symptoms are proposed 
to reflect the manifestations of the side-effects of medications, affective 
symptoms and limited social stimulation (Kirkpatrick, 2014).  
 
Negative symptoms are associated with cognitive, social and functional 
impairment in schizophrenia (Bottlender et al., 2010; Fulford et al., 2013; 
Kirkpatrick, 2014). Negative symptoms are enduring and more refractory to 
antipsychotic treatment than positive symptoms (Kirkpatrick et al., 2006; 
Levine and Leucht, 2013; Ventura et al., 2015).  
 
Negative symptoms have been suggested to be multidimensional and have 
been dissected into subgroups according to clinical characteristics. In the 
SANS, negative symptoms are divided into the five following dimensions: 
affective flattening, alogia, avolotion-apathy, anhedonia-asociality and 
attention (Andreasen, 1983) (Table 5). Based on this division, negative 
symptoms have been found to coalesce into at least two separable dimensions 
(1) an expressive factor consisting of affective flattening and alogia and (2) an 
avolition factor consisting of avolition, anhedonia and asociality (Blanchard 
and Cohen, 2006; Kirkpatrick, 2014) (Figure 1).  
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Figure(1.( A! simplified! hierarchical! classification! of! positive! and! negative! symptoms! in!
relation!to!underlying!cognitive!impairment!(Andreasen!et(al.,!1983T!Andreasen!et(al.,!1984).!
Note!that!symptoms!of!reality!distortion!do!not!associate!strongly!with!cognitive!impairment.!
 
2.4.( COGNITIVE(IMPAIRMENT(IN(SCHIZOPHRENIA(
Patients with schizophrenia typically present with cognitive impairment 
(Keefe and Reichenberg, 2014). Evidence suggests that cognitive performance 
is typically 1-2 standard deviations lower in indivuduals with schizophrenia 
than in age-matched nonaffected peers. Subclinical cognitive impairment has 
also been observed among a proportion of first-degree relatives of subjects 
with schizophrenia, suggesting that cognitive impairment is associated with 
genetic liability (Faraone et al., 1999; Tuulio-Henriksson et al., 2003; Kuha et 
al., 2007). 
Cognitive!
impairment
Positive!
symptoms
Symptoms!of!
reality!distortion
Delusions
Hallucinations
Disorganized!
symptoms
Bizarre!
behaviour
Formal!thought!
disorder
Negative!
symptoms
Motivational!
deficits
Avolition
Anhedonia
Asociality
Expressive!
deficits
Restricted!affect!
Alogia
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Cognitive impairment typically manifests prior to the onset of first psychotic 
symptoms and remains relatively stable after the remission of positive 
symptoms (Fioravanti et al., 2005; Lewandowski et al., 2011; Rapoport et al., 
2012; Nuechterlein et al., 2014). Evaluation of cognitive impairment is used in 
clinical practice both as a predictor of functional outcome and to aid the 
planning of rehabilitation interventions (Green et al., 2000; Lepage et al., 
2014; Bechi et al., 2015).  
Cognitive impairment in schizophrenia is relatively unspecific and has been 
found to be associated with various domains of cognitive functioning, 
including language functions, executive functioning (reasoning, problem 
solving), speed of processing, attention, working memory, verbal learning and 
memory, visual learning and memory, verbal comprehension, social cognition 
and motor skills (Tuulio-Henriksson et al., 2003; Paunio et al., 2004; 
Fioravanti et al., 2005; Hennah et al., 2005; Mesholam-Gately et al., 2009; 
Gur et al., 2011; Lesh., 2011; Barch et al., 2012; Catts et al., 2013; Schaefer et 
al., 2013).  
Recently, the National Institute of Mental Health (NIMH) launched the 
Measurement and Treatment Research to Improve Cognition in Schizophrenia 
(MATRICS) initiative to validate specific clinically relevant areas of cognition 
in order to standardize the assessment of treatment efficacy on cognition in 
clinical trials (Green and Nuechterlein, 2004; Nuechterlein et al., 2014). The 
MATRICS panel suggested that seven cognitive domains be assessed when 
evaluating treatment efficacy: (1) processing speed, (2) attention/vigilance, (3) 
working memory, (4) verbal learning, (5) visual learning, (6) reasoning and 
problem solving and (7) social cognition.  
Both negative and disorganized symptoms have been found to be associated 
with impairment in several neurocognitive domains. Although impairment is 
relatively generalized, some areas of cognition have been studied more than 
others. Disorganized symptoms have been associated with deficits involving 
intelligence, attention span, sensory motor function and poor concept 
attainment (Basso et al., 1998; O’Leary et al., 2000). Negative symptoms have 
been associated with deficits involving verbal learning and memory, verbal 
fluency, visual memory, visual motor sequencing, intelligence, executive 
function, sustained attention and sensory motor function (Basso et al., 1998; 
O’Leary et al., 2000). 
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2.5.( EARLY(PHASES(OF(SCHIZOPHRENIA(
Characterization of the longitudinal course of schizophrenia has found that 
symptoms and functional impairment typically emerge years before the onset 
of overt psychotic symptoms (Häfner and Maurer, 2006).  
Subtle developmental abnormalities during childhood (neurological, 
emotional, social and cognitive) have been reported in prospective studies 
among subjects who later develop schizophrenia (Isohanni et al., 2000; Mäki 
et al., 2005; Niemi et al., 2005; Insel, 2010; Rapoport et al., 2012). 
The prodromal phase of schizophrenia has been defined as the period between 
the onset of behavioural change in a person and the onset of psychotic 
symptoms (Yung et al., 1996). A constellation of symptoms, including 
depressive symptoms, anxiety, dysphoria, negative symptoms and non-
specific subjective experiences, also typically increasingly manifest during 
progression of the disorder (Häfner et al., 2003). Depressive symptoms are 
particularly common among individuals who later develop schizophrenia, with 
approximately 85% of patients presenting with depressive symptoms during 
the early course of the disorder and 25% presenting with depressive symptoms 
upon first admission (Häfner and Maurer, 2006). Increasing symptom 
severity typically presents with increasing functional (social, occupational and 
academic) impairment (Häfner et al., 2003). Some authors have dissected the 
prodromal phase into two phases with respect to the presentation of overt 
psychotic symptoms: a prepsychotic prodromal stage (mean duration 4.8 
years) and a psychotic prephase (mean duration 1.3 years) (Häfner and 
Maurer, 2006). The psychotic prephase is characterized by the presentation of 
brief and attenuated psychotic symptoms, which eventually give way to overt 
psychotic symptoms. The duration of untreated psychosis is inversely 
associated with functional outcome, emphasizing the role of early intervention 
as a means to improve treatment outcome (Penttilä et al., 2014). 
Early intervention strategies have been developed for the detection of subjects 
presenting with attenuated or brief psychotic symptoms and those with an 
elevated risk of psychosis (Häfner et al., 1992; McGlashan, 1998; Miller et al., 
2003).   
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2.6.( AETIOLOGICAL(MODELS(OF(SCHIZOPHRENIA(
Individuals with schizophrenia have been found to present with a small but 
significant reduction in intracranial volume and a reduction in total brain 
volume, with respect to both total grey and white matter (Fusar-Poli et al., 
2013; Haijma et al., 2013). Although widely investigated, the clinical utility of 
brain imaging findings remains limited. Several aetiological models have been 
put forth to describe and integrate the postulated biological and psychological 
mechanisms underlying the disorder (Linscott and Van Os, 2010; Howes and 
Murray, 2014; Howes et al., 2015).  
From a historical perspective, schizophrenia was once considered to be a 
neurodegenerative disorder, with a deteriorating course, the biological onset 
of which was thought to correlate with the manifestation of symptoms, 
typically during early adulthood (Weinberger, 1995). The neurodevelopmental 
model of schizophrenia was based on observations describing an association 
between obstetric complications and increased schizophrenia risk and 
evidence suggesting that brain imaging findings did not show significant 
progression after disease onset (Lewis and Murray, 1987; Murray and Lewis, 
1987; Weinberger, 1987). However, today some research indicates that 
extended periods of symptom relapse may be associated with reductions in 
brain volume (Andreasen et al., 2013) and that reductions in brain volume 
may even be associated with the use of antipsychotic medictions (Guo et al., 
2015). Findings describing the interaction between genetic liability and 
obstetric complications in relation to increased schizophrenia risk and the 
presence of subtle deviations in emotional, cognitive and motor development 
in children prior to the onset of schizophrenia have complemented the model 
(Cannon et al., 1989; Howes and Murray, 2014).  A reductionistic “two hit” 
model was later put forth to exemplify the longitudinal relationship between 
cumulative environmental insults with the potential to impact the 
neurodevelopmental process (Keshavan et al., 2011). In this model, genetic 
susceptibility, in combination with pre- or perinatal factors, was suggested to 
exert a subtle disruptive effect on the neurodevelopmental process upon birth, 
decreasing the threshold for developing the disorder upon encounter with 
future environmental adversities. 
 
The dopamine hypothesis was based on findings demonstrating that the 
administration of drugs that increase dopamine transmission (e.g. 
amphetamine) cause schizophrenia-like symptoms, whereas the 
administration of drugs that decrease dopamine transmission (e.g. reserpine) 
reduce schizophrenia-like symptoms (Howes et al., 2015). Further evidence of 
the central role of dopamine in schizophrenia came from widely replicated 
findings showing that antipsychotics reduce psychotic symptoms by blocking 
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striatal dopamine D2/3 receptors (Carlsson., 1977; Howes et al., 2012; 
Dragicevic et al., 2015; Howes et al., 2015; Sarpal et al., 2016). An association 
between the D2-receptor gene and schizophrenia was also found in the most 
recent GWAS (Schizophrenia Genomics Consortium, 2014). However, in a 
meta-analysis of more than 50 brain imaging studies focusing on the striatal 
dopamine system in schizophrenia the alterations in postsynaptic D2/3 
receptor availability were small and inconsistent and the presynaptic 
dopamine transporter availability did not differ among cases and controls 
(Howes et al., 2012). The meta-analysis of Howes et al. (2012) corroborated 
previous evidence suggesting that schizophrenia was associated with 
increased presynaptic dopamine synthesis capacity, dopamine release and 
increased baseline synaptic dopamine concentrations.  
The presynaptic dysregulation of dopamine has been suggested to be 
susceptible to the influence of environmental factors, including pre- and 
perinatal factors and stressful lifetime events during childhood (Howes and 
Murray, 2014; Howes et al., 2015). In animal studies, prenatal infection, 
Caesarean section and mild prenatal/perinatal hypoxia have been found to be 
associated with elevated dopamine synthesis and sensitization of the 
dopaminergic system (Howes and Murray, 2014). Subjects with a history of 
low maternal care during childhood have shown increased striatal dopamine 
release upon stressful events, suggesting sensitization of the dopaminergic 
system to early psychosocial stress (Howes and Murray, 2014). Preclinical 
findings indicate that aberrant neurodevelopment may influence the 
dopamine system. For example, in an animal model the transient knockdown 
of DISC1 expression during the pre- and perinatal stages of development has 
been demonstrated to be associated with abnormalities in postnatal 
mesocortical dopaminergic transmission and behavioural abnormalities after 
puberty (Niwa et al., 2010). 
Glutamate is the primary excitatory neurotransmitter of the central nervous 
system (Kim et al., 1980). The glutamate hypothesis suggests that N-methyl-
D-aspartic acid (NMDA) receptor dysfunction (hypofunction) is involved in 
the pathogenesis of schizophrenia (Stone et al., 2011). The role of 
glutamatergic transmission in schizophrenia is based on observations 
describing positive, negative and cognitive symptoms elicited upon the 
administration of NMDA receptor antagonists ketamine, dizocilpine and 
phencyclidine respectively (Howes et al., 2015). Some studies have suggested 
that agonists of the NMDA receptor (glycine or D-serine), acting at the glycine 
modulatory site on the NMDA receptor, are associated with improvement in 
residual positive and negative symptoms in patients with schizophrenia when 
co-administered with antipsychotic treatment (Tsai and Lin, 2010). NMDA 
receptor hypofunction in prefrontal gamma-aminobutyric acid (GABA) 
interneurons has been suggested to be associated with a reduction in the 
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inhibitory regulatory capacity of the prefrontal cortex over dopaminergic 
mesolimbic structures, resulting in hyperactive mesolimbic dopamine D2 
transmission and psychotic symptoms (Nakazawa et al., 2012). Dopamine and 
glutamate theories have been suggested to converge in relating prefrontal 
glutamatergic hypofunction with subcortical hyperdopaminergic transmission 
(Howes et al., 2015). An association between several glutamate receptor genes 
and schizophrenia was also replicated in the most recent GWAS 
(Schizophrenia Genomics Consortium, 2014). One of the genes identified in 
the study, the metabotropic glutamate receptor 3 (GRM3), has also been found 
to interact with severe obstetric complications, with a concomitant decrease in 
hippocamppal volume (Haukvik et al., 2010). GRM3 mRNA has also been 
observed to be downregulated in response to ischaemia (Raghavendra Rao et 
al., 2002; Lu et al., 2004).  
 
2.7.( RISK(FACTORS(
Both genetic and environmental factors mediate schizophrenia risk (Sullivan 
et al., 2012). Schizophrenia has been associated with heritability estimates of 
up to 81%, compared with heritability estimates of 75% for bipolar disorder 
and 37% for major depressive disorder, suggesting that schizophrenia is 
associated with a strong genetic component, equivalent to that of autism 
spectrum disorders (ASDs) (80%) (Sullivan et al., 2012). Environmental 
factors play an important role in the pathophysiology of schizophrenia as well 
(Brown, 2011a), and the role of obstetric complications is widely 
acknowledged (Cannon et al., 2002a).  
2.7.1.( GENETIC(RISK(FACTORS(
The genome consists of approximately 3 billion base pairs, the vast majority of 
which (>98%) comprise of non-coding sequence, containing regulatory 
elements and sequences of yet unknown function, the remainder (<2%) being 
protein coding sequence (www.genome.gov). Any two individuals are 
genetically 99.9% identical. Identification of the genetic variation in the 
remaining 0.1% of the genome, which is associated with morbidity, is thus 
challenging and requires increasingly larger samples to detect the subtle 
differences in genetic variation conferring genetic risk in a population. Most 
of the variation in the genome is associated with sequences of a small 
individual effect on morbidity. Of all human proteins (n=19 692), 67% are 
expressed in the brain (www.humanproteinatlas.org). The variation of single 
nucleotides in the genome is arbitrarily considered common if it occurs in >1% 
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of the population, referred to as a single-nucleotide polymorphism (SNP), and 
rare if it occurs in <1% of the population, referred to as a single-nucleotide 
variation (SNV). Larger deletions and duplications in the genome, termed 
copy number variants (CNVs), are typically of larger effect size, i.e. exert a 
more substantial effect on phenotype (Sullivan et al., 2012). Genetic variation 
is transmitted though generations or it can occur as a result of spontaneous 
(de novo) mutations (Sanders et al., 2012; Fromer et al., 2014).  
Compared with most populations in Europe, the Finnish population exhibits 
less genetic diversity and more linkage disequilibrium (LD) (Sajantila et al., 
1996; Varilo et al., 2003; Jakkula et al., 2008). One consequence of this is the 
Finnish Disease Heritage, a group of 36 rare hereditary, monogenic diseases 
that are more prevalent in Finland than elsewhere in the world 
(http://www.findis.org/heritage.html). These diseases have been found to 
cause mental retardation, visual impairment, congenital malformations, bone 
disorders, hearing loss, metabolic disturbances, epileptic or deteriorating 
neurological diseases, blood disorders and multisystemic syndromes (Norio, 
2003).  
Isolates, founded by a small group of settlers experiencing significant 
population growth, present with elevated levels of LD and exhibit fewer 
regions of very low LD relative to outbred populations (Service et al., 2006). 
Population isolates, which exhibit both genetic and environmental 
homogeneity, have been ulitized in the identification of rare genetic variants 
enriched in specific subpopulations segregating with complex genetic 
disorders including schizophrenia (Hovatta et al., 1999; Myles-Worsley et al., 
1999; Peltonen et al., 2000; DeLisi et al., 2002; Jakkula et al., 2008; Åberg et 
al., 2008; Paunio et al., 2009; Myles-Worsley et al., 2011; Peltola et al., 2016). 
The Finnish population contains several isolates (Jakkula et al., 2008). 
The Finnish Internal Isolate in Northeastern Finland was originally founded 
in the 17th century by 34 families (Hovatta et al., 1997). Until World War II, 
the population of the internal Isolate remained relatively isolated. In the 
Isolate, people have predominantly found spouses from the same village, and 
even marriages between people living in northern and southern parts of the 
same municipality have been rare. The estimated kinship coefficient is 1.43 
times higher than the expected value (Paunio et al., 2009). After World War 
II, emigration from the municipality to southern Finland increased, whereas 
immigration into the municipality remained limited (Hovatta et al., 1999). 
Due to the small number of founders and rapid expansion, the population in 
the region is genetically more homogeneous and LD is higher than in the rest 
of Finland or in other isolates investigated throughout the world (Varilo et al., 
2003; Service et al., 2006; Jakkula et al., 2008). The lifetime risk of 
schizophrenia in the Isolate region is elevated (3.2%) relative to the rest of 
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Finland and other populations (Hovatta et al., 1997; Saha et al., 2005; 
McGrath et al., 2008). Some differences between the Isolate and the rest of 
Finland have been reported with respect to both susceptibility loci and 
frequency of specific risk alleles (Paunio et al., 2001; Hennah et al., 2003; 
Paunio et al., 2004; Wedenoja et al., 2008; Wessman et al., 2009; Wedenoja 
et al., 2010; Stoll et al., 2013; Peltola et al., 2016). For example, an intragenic 
short tandem repeat allele within the Reelin gene, which has been found to be 
associated with moderate cognitive impairment in the rest of Finland, is 
almost absent in individuals originating from the Isolate (Wedenoja et al., 
2008; Wedenoja et al., 2010). Conversely, a deletion encompassing the the 
topoisomerase 3β (TOP3β) gene, associated with a 2-fold risk of 
schizophrenia, is enriched in the internal Isolate (Stoll et al. 2013). 
Investigation of symptom dimensions between individuals with schizophrenia 
in relation to the Isolate region and the rest of Finland found that individuals 
with schizophrenia descending from the Isolate presented with less positive 
symptoms (delusions and hallucinations) than individuals with schizophrenia 
deriving from the rest of Finland, which was suggested to be related to the 
genetic homogenicity of the Isolate (Arajärvi et al., 2006).  
 
GENOME[WIDE(ASSOCIATION(STUDIES((
(
Recent GWASs investigating the association of common genetic variability of 
small effect size on morbidity in large multinational population-based samples 
have shed increasing light on common gene variants associated with 
schizophrenia (Schizophrenia Genomics Consortium, 2014).  
 
In the most recent GWAS to date, encompassing 36 989 subjects with 
schizophrenia, 108 loci meeting genome-wide significance were identified 
(Schizophrenia Genomics Consortium, 2014). Of these loci, 75% were found to 
associate with protein-coding regions, and 8% were found to be within close 
proximity (<20 kb) to protein coding regions. The study corroborated previous 
findings describing variants associated with pre-existing biologically relevant 
aetiological determinants of schizophrenia, including genes involved in (1) 
dopamine signalling (D2-dopamine receptor), (2) glutamate signalling, (3) 
calcium signalling, (4) synaptic functioning and plasticity, (5) potassium and 
cholinergic signalling, and (5) neurodevelopment (Table 6). 
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COPY(NUMBER(VARIATIONS(
 
CNVs are large deletions, duplications or rearrangements in the genome, 
typically >1 kb in size (Heyes et al., 2015). Genetic research on 
neurodevelopmental disorders has focused on the role of CNVs of large effect 
size (Purcell et al., 2014; Sanders et al., 2015). Large CNVs are found in 3.3% 
of individuals with ASDs and in 2.4% of individuals with schizophrenia, 
compared with 0.5% of individuals without these disorders (Kirov, 2015). 
CNVs have been reported to be associated with a 2- to 50-fold increase in 
schizophrenia risk (Sullivan et al., 2012; Kirov, 2015). At least 11 CNVs have 
been shown to increase schizophrenia risk, including deletions at 1q21.1, 3q29, 
15q11.2, 15q13.3 and 22q11.2 and duplications at 1q21.1, 7q11.23, 15q11.2- 
q13.1, 16p13.1 and 16p11.2 (Kirov, 2015). Many of the identified CNVs are 
pleiotropic in that they associate with several neurodevelopmental outcomes, 
including cognitive deficits, mental retardation, epilepsy, ASDs and 
schizophrenia (Szatkiewicz et al., 2014). Interestingly, female sex has been 
associated with an elevated mutation burden, implying that larger CNVs are 
required for clinical manifestations to take effect in females than in males, 
sometimes referred to as the ‘female protective model’ (Jacquemont et al., 
2014). However, in a proportion of individuals carrying CNVs only a modest 
effect on cognitive traits has been observed (Stefansson et al., 2014).  
The mechanisms underlying the relationship between neurodevelopment and 
dopaminergic dysfunction in relation to psychosis have been investigated 
among individuals presenting with the 22q11.2 deletion syndrome, in which a 
large deletion on chromosome 22q11.2 has been found to be associated with 
both neurodevelopmental outcomes and a 25-fold increased risk of developing 
schizophrenia (Karayiorgou et al., 2010; Rees et al., 2014; Schneider et al., 
2014; Vasa et al., 2015). Up to 40% of 22q11.2 deletion subjects have been 
reported to develop a psychotic disorder by adulthood (Schneider et al., 2014). 
There is some evidence that duplications in the 22q11.2 region may reduce 
schizophrenia risk, suggestive of a genetically conferred protective function 
(Rees et al., 2014). Longitudinal investigation of the premorbid phase among 
22q11.2 deletion subjects has found that psychotic symptoms are preceded by 
cognitive decline (Vorstman et al., 2015). Most of the genes within 22q11.2 are 
expressed in the brain, of which the catecholamine-O-methyl-transfrease 
(COMT) gene has been widely investigated in relation to schizophrenia risk 
(Caspi et al., 2005; Karayiorgou et al., 2010). Recently, a deletion in 22q11.22, 
encompassing the TOP3β gene, was found to be associated with cognitive 
impairment and schizophrenia in a Finnish study sample (Stoll et al., 2013).  
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DISC1((
 
The gene DISC1 was originally identified in a large Scottish pedigree, in which 
a chromosomal translocation was found to segregate with severe mental 
illness (St Clair et al., 1990; Blackwood et al., 2001). Identification of a 
breakpoint on chromosome 1q42 led to the identification of two genes directly 
disrupted by the translocation, which were named Disrupted in Schizophrenia 
1 and 2 (DISC1 and DISC2), respectively (Millar et al., 2000). Evidence of 
linkage and association at 1q42 and in particular DISC1 in relation to 
schizophrenia susceptibility has subsequently been replicated in the Finnish 
schizophrenia family cohort (Ekelund et al., 2001; Hennah et al., 2003; 
Ekelund et al., 2004; Hennah et al., 2004). Various proteins, including the 
amyloid precursor protein (APP), DIX domain containing 1 (Dixdc1), 
lissencephaly-1 (LIS1), NDE1, NDEL1, PDE4B and PDE4D, which have been 
found to interact with DISC1, have also been associated with 
neurodevelopmental outcomes and increased schizophrenia risk (Kamiya et 
al., 2006; Hennah and Porteous, 2009; Bradshaw and Porteous, 2012; Soda 
et al., 2013). Of these genes, NDE1, NDEL1, PDE4B and PDE4D have been 
associated with schizophrenia in the Finnish schizophrenia family cohort 
(Hennah et al., 2007; Tomppo et al., 2009).  
 
Since its discovery by Millar et al. (2000), many researchers have investigated 
the functions of DISC1, which has since been found to play a role in neuronal 
proliferation and migration, neurite outgrowth, maintenance of synapse 
composition and glutamatergic and dopaminergic neurotransmission (Millar 
et al., 2003; Higginbotham and Gleeson, 2007; Niwa et al., 2010;  Brandon 
and Sawa, 2011; Ishizuka et al., 2011; Lee et al., 2011; Eykelenboom et al., 
2012; Lepagnol-Bestel et al., 2013; Steinecke et al., 2014; Devine et al., 2016; 
Tang et al., 2016).  
Emerging evidence suggests that DISC1 is involved in the regulation of 
neuronal cell division and the maintenance of neuronal and synaptic 
morphology by mediating the intracellular trafficking of proteins, protein 
complexes, organelles, vesicles, mitochondria, neurotransmitters and ion 
channels within neurons (Devine et al., 2016). DISC1 has been found to 
localize to different intracellular compartments including mitochondria, the 
nucleus, the centrosome, the Golgi apparatus and the endoplasmic reticulum 
(Millar et al., 2005a; Higginbotham and Gleeson, 2007; Lepagnol-Bestel et al., 
2013; Park et al., 2015), and its intracellular localization has been postulated 
to be disrupted upon truncation (Devine et al., 2016). DISC1-mediated 
intracellular transport has been proposed to occur via its interaction with a 
number of specific binding partners, adaptor and motor proteins such as 
microtubules, actin and kinesin-associated proteins, fasciculation and 
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elongation protein zeta 1 (FEZ1), β4-spectrin, dynactin, intersectins, inesins, 
glycogen synthase kinase 3 beta (GSK3β), NDE1 and NDEL1 (Devine et al., 
2016). It has been proposed that DISC1 may be involved in mediating antero- 
and retrograde axonal transport within the cell (Devine et al., 2016). !
To date, over 50 DISC1 mRNA splice variants have been identified, with 
different variants being differentially expressed during different periods in 
neurodevelopment, with the expression of some variants peaking during 
distinct periods of foetal life (Nakata et al., 2009). This is reflective of the 
complexity of transcriptional and translational regulatory processes involved 
in development.  
NDE1(and(NDEL1(
 
NDE1 and NDEL1 are coiled-coil proteins that bind to and form complexes 
with LIS1 (Derewenda et al., 2007). NDEL1 and NDE1 also interact with the 
cytoskeletal motor protein dynein, which forms a functional link between both 
proteins and microtubules, in the regulation of mitosis, cell migration, and 
microtubule-associated intracellular transport processes (McKenney et al., 
2010; Bradshaw, 2016). Both NDEL1 and NDE1 have been found to interact 
directly with DISC1 (Gadelha et al., 2013; Bradshaw, 2016). Both are critical 
for cortical development (Shu et al., 2004; Pei et al., 2014). 
The NDEL1 gene, comprising 10 exons, is situated in the 17q13.1 region 
(Hayashi et al., 2005). The interaction of DISC1 and NDEL1 has been 
suggested to regulate neuronal morphogenesis and neuronal positioning 
during neuronal integration (Duan et al., 2007). NDEL1 has been associatied 
with increased schizophrenia risk in the Finnish schizophrenia family study 
sample (Tomppo et al., 2009). The enzyme activity of NDEL1 has been 
reported to be reduced in the plasma of schizophrenia patients (Gadelha et al., 
2013).  
The NDE1 gene is situated in the 16p13.11 region. Deletions in 16p13.11 have 
been associated with autism, epilepsy and intellectual disability (Ullmann et 
al., 2007; Hannes et al., 2009; de Kovel et al., 2010; Heinzen et al., 2010; 
Mefford et al., 2010; Mullen et al., 2013). Functional mutations and deletions 
in the NDE1 gene have been associated with marked neurodevelopmental 
outcomes, including failure of neurogenesis and deficient cortical lamination 
(Alkuraya et al., 2011; Bakircioglu et al., 2011; Paciorkowski et al., 2013). 
DISC1 has been found to moderate the association of NDE1 and GSK3β with 
the trafficking kinesin protein 1 (TRAK1) in the cyclic adenosine 
monophosphate (cAMP)-mediated regulation of axonal mitochondrial 
transport (Ogawa et al., 2016). In a mouse model, NDE1 has been found to be 
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expressed in the subventricular zone of the forebrain and the subgranular zone 
of the hippocampus (Pei et al., 2014). Knockdown of NDE1 in zebrafish 
embryos has been found to result in the suppression of neuronal cell division, 
leading to left–right patterning defects, implicating NDE1 in the lateralization 
of the central nervous system (Kim et al., 2011). Variants of NDE1 have been 
associated with increased schizophrenia risk (Hennah et al., 2007; Moens et 
al., 2011; Kimura et al., 2015). 
 
PDE4B(and(PDE4D(
(
PDEs constitute a family of 11 different enzymes (PDE1–PDE11) encoded by 
21 genes, the majority of which are expressed as multiple variants of up to 100 
individual proteins (Ricciarelli and Fedele, 2015). The intracellular 
inactivation of the second messenger cAMP is controlled by PDE4 by 
degradation of cAMP to inactive AMP, attenuating cAMP-mediated 
intracellular signalling. PDE4D has been found to associate with memory 
functions (Ricciarelli and Fedele, 2015). PDE4B is known to be a target of 
antidepressant rolipram (Millar et al., 2005b). PDE4B and PDE4D have been 
associated with increased schizophrenia risk (Tomppo et al. 2009). The 
interaction of DISC1 and PDE4 has been shown to play an important role in 
the functional activity of NDE1 (Bradshaw et al., 2011). 
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2.7.2.( ENVIRONMENTAL(RISK(FACTORS(
 
Environmental risk factors associated with schizophrenia risk can broadly be 
divided into (1) pre- and perinatal and (2) postnatal (premorbid) risk factors 
(Brown, 2011a; Rapoport et al., 2012).  
2.7.2.1.( PRE[(AND(PERINATAL(ENVIRONMENTAL(RISK(FACTORS(
 
Obstetric complications have collectively been associated with a 2-fold 
increase in the risk of developing schizophrenia, highlighting the relationship 
between neurodevelopment and schizophrenia (Murray and Lewis, 1987; 
Weinberger et al., 1987; Geddes and Lawrie, 1995; Cannon et al., 2002a; 
Clarke et al., 2006; Brown, 2011a; Rapoport et al., 2012). Obstetric 
complications have also been associated with a variety of psychiatric disorders, 
for instance LBW has been associated with an increased risk of depression 
(Räikkonen et al., 2008), eating disorders (Favaro et al., 2006), attention 
deficit disorders (Banerjee et al., 2007) and autism (Schendel and Bhasin, 
2008). Obstetric complications are thus not risk factors specific to 
schizophrenia.  
In a meta-analysis on the association of obstetric complications and 
schizophrenia (Cannon et al., 2002a), consisting of eight prospective 
population-based studies, the following 10 obstetric complications were found 
to associate significantly with schizophrenia risk: diabetes in pregnancy (OR 
7.76, 95%CI 1.37–43.90), birth weight <2000 g (OR 3.89, 95%CI), emergency 
Caesarean section (OR 3.24, 95%CI 1.40–7.50), congenital malformations 
(OR 2.35, 95%CI 1.21–4.57), uterine atony (OR 2.29, 95%CI 1.51–3.50),  
rhesus variable (OR 2, 95%CI 1.01–3.96), asphyxia (OR 1.74, 95%CI 1.15–
2.62), bleeding in pregnancy (OR 1.69, 95%CI 1.14–2.52) and birth weight 
<2500 g (OR 1.67, 95%CI 1.22–2.29).  
In a Danish population-based nested case-control study consisting of 1039 
individuals with schizophrenia and 24 826 matched controls, Byrne et al. 
(2007) described an association between schizophrenia and maternal 
influenza (IRR) 8.2, 95%CI 1.4-48.8), preeclampsia (IRR 2.72, 95%CI 1.0- 
7.3), haemorrhage during delivery (IRR 2.43, 95%CI 1.1-5.6), maternal sepsis 
of childbirth and the puerperium (IRR 2.91, 95%CI 1.1-7.9), threatened 
premature delivery (IRR 2.39, 95%CI 1.4-4.1), manual extraction of the baby 
(IRR 2.15, 95%CI 1.1-4.4), non-attendence of antenatal appointments (IRR 
2.08, 95%CI: 1.0-4.4) and gestational age of 37 weeks or below (IRR 1.51, 
95%CI 1.0-2.2).  
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Pre- and perinatal factors associated with schizophrenia can be grouped into 
the following categories: (1) prenatal immunological factors, (2) prenatal 
maternal stress, (3) pre- and perinatal hypoxia, (4) maternal prenatal 
nutrition, and (5) factors related to foetal growth (Clarke et al., 2006). The 
categorical division of environmental factors is acknowledged to be 
reductionistic in that different environmental exposures co-precipitate and 
influence one another. For instance, gestational diabetes has been found to be 
associated with immune system activation, increased oxidative stress, foetal 
hypoxia and deviant intrauterine growth, and thus, causal inferences are 
potentially confounded by complexity (Van Lieshout and Voruganti, 2008). 
Moreover, the categorical division of environmental factors with respect to the 
foetomaternal boundary often neglects the central role occupied by the 
placenta in relation to foetal growth (Patterson, 2007).  In addition to 
regulating the selective permeability of nutrients, oxygen and antibodies to the 
foetus, it constitutes an immunological interface between the mother and the 
foetus, promoting maternal tolerance to the developing foetus (Hsiao and 
Patterson, 2012). 
 
The relationship between prenatal maternal infection and schizophrenia 
gained momentum when Mednick et al. (1988) described an association 
between schizophrenia and prenatal exposure to influenza among subjects 
born in Helsinki during the 1957 epidemic. Other prenatal viral and bacterial 
microbial infections (Rubella, toxoplasma, herpes simplex virus type 2) have 
since been found to be associated with increased schizophrenia risk (Brown 
and Derkits, 2010). Prenatal infection has been found to interact with genetic 
liability in increasing schizophrenia risk (Clarke et al., 2009; Blomström et al., 
2016). Maternal infections during pregnancy requiring hospitalization in 
combination with both (1) autoimmune disorders and (2) anaemia during 
pregnancy have been found to exert additive effects on schizophrenia risk 
among offspring (Benros et al., 2011; Nielsen et al., 2016). Elevated maternal 
C-reactive protein levels during pregnancy have been associated with an 
increased risk of both ASDs and schizophrenia among offspring (Canetta et 
al., 2014; Knuesel et al., 2014). Interestingly, however, individuals who 
develop non-affective psychoses have also been found to have decreased levels 
of certain acute-phase proteins at birth (Gardner et al., 2013; Blomström et 
al., 2015). The potential molecular mechanisms underlying the association 
between prenatal infection and schizophrenia remain unsubstantiated, but it 
has been suggested that the activation of the immune system is in itself a 
central mediator of schizophrenia risk (Muller et al., 2015). A proposed 
mechanism suggests that an increase in the permeability of the blood-brain 
barrier may upon infection/inflammation result in an influx of 
proinflammatory cytokines into the central nervous system of the foetus, with 
implications on neurodevelopment (Brown, 2011b).  
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Rhesus (Rh) incompatibility during pregnancy, an example of maternal-foetal 
genotype incompatibility, has been associated with increased schizophrenia 
risk, after a previous Rh-incompatible pregnancy (Kraft et al., 2004). Rh 
incompatibility disease has been associated with foetal hypoxia and increased 
levels of unconjugated bilirubin, which is known to exert neurotoxic effects 
(Morioka et al., 2015). Interestingly, evidence also suggests that the Human 
Leukocyte Antigen-B (HLA-B) locus increases schizophrenia risk among 
female offspring when mothers and their daughters match and are ”too alike” 
with respect to alleles at the HLA-B locus (Palmer et al., 2006).  
In 1978, Huttunen and Niskanen described an association between paternal 
death, a proxy for maternal stress, during pregnancy and increased 
schizophrenia risk among offspring. The association between maternal stress 
during pregnancy and schizophrenia has since been replicated. Pregnancies 
during the invasion of the Netherlands by Germany in World War II and 
during the Israeli Six Day War were found to be associated with an increased 
schizophrenia risk among offspring (van Os and Selten, 1998; Malaspina et al., 
2008). In a large population cohort consisting of 1.38 million Danish births 
from 1973 to 1995, Khashan et al. (2008) described a 1.67-fold increase in 
schizophrenia risk among offspring when mothers had been exposed to death 
of a relative during the first trimester. Additionally, increased schizophrenia 
risk has been described among offspring born to mothers who report their 
pregnancies as being unwanted (Myhrman et al., 1996; Herman et al., 2006). 
However, in a recent study by Abel et al. (2014) comprising 1 045 336 Swedish 
births between the years 1973 and 1985 an association was described between 
postnatal but not prenatal maternal bereavement stress and an increased risk 
of psychosis among offspring. The observed association was not mediated by 
family history of psychotic disorders. 
It has been suggested that the biological mechanisms underlying the 
association between maternal stress during pregnancy and increased 
schizophrenia risk among offspring may involve foetal exposure to 
glucocorticoids, inflammation, placental factors or factors related to maternal 
health (Brown, 2011b). Stressful life events during pregnancy have been 
associated with LBW (Khashan et al., 2008), which is also a schizophrenia-
associated risk factor (Cannon et al., 2002a). 
Pre- and perinatal hypoxia has been suggested to interact with genetic liability, 
increasing schizophrenia risk (McNeil et al., 1999; Stefanis et al., 1999; Rosso 
et al., 2000; Cannon et al., 2002b; Van Erp et al., 2002; Schulze et al., 2003; 
Ebner et al., 2008; Haukvik et al., 2010). Pre- and perinatal hypoxia has also 
been observed to be associated with cognitive and behavioural outcomes 
during childhood (Goldstein et al., 2000). Chronic prenatal and acute 
perinatal hypoxia have been suggested to exert a differential effect on 
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neurodevelopment (Anastario et al., 2012). Maternal smoking during 
pregnancy, which is associated with chronic foetal hypoxia, has also been 
found to associate with increased schizophrenia risk (Niemelä et al., 2016) and 
greater severity of negative symptoms among offspring who develop 
schizophrenia (Stathopoulou et al., 2013). The frequency of acute perinatal 
hypoxia, as indicated by lower Apgar 5 min scores, has been suggested to be 
elevated in at-risk mental state subjects relative to healthy controls (Kotlicka-
Antczak et al., 2014). Evidence suggests that disrupted neurotrophic signalling 
may contribute to hypoxia-related outcome measures, and perinatal hypoxia 
has been associated with a 20% decrease in brain-derived neurotrophic factor 
(BDNF) levels in neonatal cord blood samples of subjects who develop 
schizophrenia (Cannon et al., 2008).  
Preliminary evidence suggesting an association between prenatal malnutrition 
and schizophrenia came from studies describing the effects of in utero 
exposure to famine in the Dutch Hunger Winter of 1944-1945 (Brown and 
Susser, 2008). A direct association between nutritional deprivation and 
schizophrenia in famine was difficult to decipher since famine is also 
associated with other environmental factors, including infection and stress, 
both of which have been associated with schizophrenia (Brown, 2011a). In 
animal models, prenatal protein deprivation has been associated with 
structural central nervous system (CNS) manifestations and cognitive 
outcomes among offspring (Meyer and Feldon, 2010).  
Both decreased and increased concentrations of neonatal vitamin D have been 
associated with increased schizophrenia risk (McGrath et al., 2010), and 
decreased maternal concentrations of 25(OH)D (a metabolite of vitamin D) 
have been associated with foetal growth restriction, increased risk of preterm 
birth and small size for gestational age at birth (Miliku et al., 2016).  
Maternal iron deficiency during pregnancy has been associated with 
neurocognitive outcomes and an increased risk of schizophrenia spectrum 
disorders (SSDs) among offspring (Insel et al., 2008; Radlowski and Johnson, 
2013). Iron is essential for brain development and functioning, and iron 
deficiency has been suggested to be related to nutritional deprivation. In a 
study comprising 6872 offspring, Insel et al. (2008) described an inverse 
relationship between decreasing maternal haemoglobin concentration and 
increasing SSD susceptibility among offspring. In the study, a mean maternal 
haemoglobin concentration of < 10.0 g/dL was found to be associated with a 
4-fold increase in SSD risk. 
Maternal diabetes during pregnancy has been associated with increased 
schizophrenia risk in a meta-analysis (Cannon et al., 2002a). This finding was 
not replicated in a subsequent population-based study in the Danish 
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population (Byrne et al., 2007). The biological mechanisms underlying the 
association of maternal diabetes and schizophrenia have been suggested to 
involve factors related to immune activation, oxidative stress, hypoxia and 
deviant birth weight (Van Lieshout and Voruganti, 2008). To date, no study 
has investigated the difference in the relationship between gestational 
diabetes and maternal diabetes prior to pregnancy in relation to subsequent 
schizophrenia risk.  
 
BIRTH(WEIGHT(AND(SCHIZOPHRENIA((
 
Birth weight is mediated by two major factors: (1) duration of gestation and 
(2) intrauterine growth rate. LBW can occur as the result of either a shortened 
period of gestation or retarded intrauterine growth, and sometimes a 
combination of both (Kramer, 1987). Prematurity is defined as a gestational 
age of less than 37 weeks. Birth weight is physiologically related to gestational 
age, and prematurity and postmaturity are commonly associated with 
decreasing and increasing birth weight, respectively (Stillerman et al., 2008). 
Deviations of birth weight, both decreasing and increasing, and pre- and 
postmaturity have been associated with increased perinatal mortality and 
morbidity among offspring (Battaglia et al., 1966; Chase et al., 1969; Basso et 
al., 2006; Henriksen, 2008; Stillerman et al., 2008). The World Health 
Organization has defined LBW as a birth weight of <2500 g, based upon 
findings demonstrating that the mortality of newborns with a birth weight 
under this cut-off value is significantly increased (Kramer, 1987). The term 
intrauterine growth restriction is used to describe neonates unable to reach 
their genetically determined potential size as a result of reduced foetal growth 
due to environmental factors (Stillerman et al., 2008). Although a unitary 
definition of HBW has not been assigned, a birth weight of >4000 g or above 
the 90th percentile, has frequently been used in the literature to denote HBW, 
as elevated neonatal morbidity has been documented above this cut-off point 
(Battaglia et al., 1966; Jolly et al., 2003; Henriksen, 2008). 
 
In a large meta-analysis comprising 895 articles published in 1970-1984, the 
determinants of LBW were categorized into the following groups: (1) genetic 
and constitutional factors, (2) demographic and psychosocial factors, (3) 
obstetric factors, (4) nutritional factors, (5) maternal morbidity during 
pregnancy, (6) toxic exposures and (7) antenatal care (Table 7) (Kramer, 
1987).  
 
 
 
 46 
????????? ???????????????????????????????????????????????????????????????????????????????
????????????????????????
 
 
? ??????????
?????????????????????
??????????????????????????????? ?????? ???? ???????????????????? ???????
???????????????????????????
??????????????????????????????????????
?????????????
?????????????????????
???????????????
?????????????????????????????
????????????????????????????????????????
???????
???????????????????
??????????????????????????????????
??????????????????????????????????????????????????????????????????????????????
????????????????????
????????????????????????
????????????????????????????????????????????????????????????????
???????????????? ????????????????????????
???????????????????????????????????????????????????
???????????????????????
????????? ?????????????????????????????
????????????????????????????????????????????????????
??? ???????? ?????????????????????????
??????????????????
??????????????????????????????????
????????????????????????????????????
???????????????????
??????????????????????????????????? ???????????
?????????????????
 47 
In addition to genetic and constitutional factors, the determinants of 
HBW include: gestational age > 40 weeks, previous delivery of a macrosomic 
baby, pregestational diabetes, gestational diabetes, increased maternal age, 
increased parity, maternal pre-pregnancy weight, maternal weight gain during 
pregnancy (Jolly et al., 2003; Wallace and McEwan, 2007). Gestational 
diabetes is one of the strongest triggers of HBW (Wallace and McEwan, 2007). 
Maternal hyperglycaemia leads to elevated glucose levels in the foetus, 
resulting in foetal hyperinsulinaemia, which stimulates foetal growth (Wallace 
and McEwan, 2007). In a large study consisting of 350 311 singleton 
pregnancies in the United Kingdom born in 1988-1997, HBW was found to be 
associated with the following obstetric complications, many of which are 
associated with perinatal hypoxia: prolonged first and second stage of labour, 
instrumental vaginal delivery, third-degree perineal trauma, emergency 
Caesarean section, postpartum haemorrhage, Apgar score <4 and admission 
to the special care baby unit (Jolly et al., 2003). 
Several meta-analyses have investigated the association between obstetric 
complications and schizophrenia risk (Geddes and Lawrie, 1995; Geddes et al., 
1999; Cannon et al., 2002a). In the most recent meta-analysis, Cannon et al. 
(2002a) reported a 1.67-fold and a 3.39-fold increase in schizophrenia risk in 
relation to birth weights <2500 g and <2000 g, respectively. Several studies 
have since been published on the association between obstetric complications, 
including birth weight, and schizophrenia risk (Gunnell et al., 2003; Gunnell 
et al., 2005; Byrne et al., 2007; Abel et al., 2010; Moilanen et al., 2010; Eide 
et al., 2013; Keskinen et al., 2013; Byars et al., 2014). Some studies have failed 
to find an association between birth weight and schizophrenia (Gunnell et al., 
2005; Byrne et al., 2007). In addition, two recent large population-based 
cohort studies have described an association between birth weight and ASDs 
(Abel et al., 2013; Byars et al., 2014). The central findings in relation to the 
association of birth weight and schizophrenia are presented in Table 8. 
 
Gunnell et al. (2003) investigated the association between birth weight and 
schizophrenia in a cohort of 246 655 Swedish male conscripts, 80 of whom had 
been assigned a diagnosis of schizophrenia over a 3-year follow-up. A reverse 
J-shaped association was found between birth weight and schizophrenia in 
men, in which LBW (<25oo g) and HBW (>40oo g) were associated with an 
increase in schizophrenia risk. A subsequent investigation by Gunnell et al. 
(2005) of a larger cohort consisting of 719 476 Swedish males and females, 736 
of whom had developed schizophrenia over a 9.9-year follow-up, failed to 
detect an association between birth weight and schizophrenia. However, the 
authors concluded that they could not rule out a small increase in 
schizophrenia risk among the heavier babies (>4000 g).  
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A 34-year follow-up of the Northern Finland 1966 birth cohort (NFBC) 
comprising 12 058 subjects, 111 subjects with a diagnosis of schizophrenia, 
found that both LBW (<2500 g) (OR 2.5) and HBW (>4500 g) (OR 2.4) were 
associated with increased schizophrenia risk (Moilanen et al., 2010). Further 
investigation of the cohort, with additional 44-year follow-up data, found that 
HBW, in comparison with LBW, was associated with augmented 
schizophrenia risk, specifically among offspring with a history of parental 
psychosis, indicative of increased genetic liability, whereas LBW was 
associated with schizophrenia among offspring without a history of parental 
psychosis (Keskinen et al., 2013). This observation was suggested to be 
reflective of a potential HBW-mediated gene-environment interaction.  
 
In a large population-based cohort study comprising 1.49 million subjects 
from Sweden and Denmark, 5445 of whom had a SSD, Abel et al. (2010) 
observed an association between LBW (<2500 g) and an increased risk of 
psychotic disorders (ICD-9 diagnoses 290-319 and ICD-10 diagnoses F20-
F29). In a Norwegian population-based cohort study consisting of 873 612 
individuals, 2207 with schizophrenia born in 1967-1982, pre-eclampsia was 
proposed to mediate the association observed between LBW and 
schizophrenia, suggesting a role for placental dysfunction in relation to LBW-
associated schizophrenia risk (Eide et al., 2013). Recently, in a Danish 
population-based study consisting of 1.79 million singleton births, Byars et al. 
(2014) found that the risk of ASDs was increased among subjects with “above 
average” birth weight (3691-4090 g), whereas schizophrenia risk was 
increased among subjects presenting with “below average” birth weight (2891-
3290 g) (Byars et al., 2014). Abel et al. (2013) also investigated the association 
of birth weight and ASDs in a Swedish study sample consisting of 4283 
subjects with ASDs and 36 588 controls. In the study conducted by Abel et al. 
(2013), the risk of ASDs was found to increase in relation to both decreasing 
and increasing birth weight, in which the greatest ASD risk was observed 
among individuals presenting with a birth weight of 2.0 standard deviations 
(SDs) below or 2.0 SDs above the mean for gestational age. 
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Table(8.( Main! findings! of! the! association! between! birth! weight! and! schizophrenia! in!
studies! not! included! in! earlier! metaOanalyses.! Significant/nonsignificant! associations! have!
been!illustrated!(green/red).!
! Study(type( Sample(
size(
N(SZ(
orASD)(
Year(of(
birth(
Result((OR/HR)(
Gunnell!
et!al.!
(2003)!
PopulationO
based!cohort!
(Sweden)!
246!655!
male!
conscripts!!
80!! 1973–1980! <2500g!(HR!7.03)!>4000g!(HR!3.37)!
Gunnell!
et!al.!
(2005)!
PopulationO
based!cohort!
(Sweden)!
719!476!
males!
and!
females!!
736!! 1973–1980!! No!association!
Byrne!et!
al.!(2007)!
Population!
nested!CaseO
control!!
(Denmark)!
25!865! 1039!! 1973–1983!! No!association!
Abel!et!al.!
(2010)!
PopulationO
based!cohort!
(Sweden!and!
Denmark)!
1.49!
million!! 5445*!
1973O1984!
(Sweden)!!
!
1979O1986!
(Denmark)!
500O1499g!!!(OR!1.72)!!
1500O1999g!(OR!1.55)!!
2000O2499g!(OR!1.50)!!
2500O2999g!(OR!1.27)!
3000O3499g!(OR!1.10)!!
Eide!et!al.!
(2013)!
PopulationO
based!cohort!
study!(Norway)!
873!612!! 2207!! 1967O1982! 500–2499g!(OR!1.5)!
Byars!et!
al.!(2014)!
PopulationO
based!cohort!
(Denmark)!
1.79!
million!!
95345!
had!a!SZ!
spectrum!
or!an!
ASD!!
1978O2009!! 2891O3290g!(SZ)!3691O4090g!(ASD)!
Moilanen!
et!al.!!
(2010)!
Prospective!
birth!cohort!
(Finland)!
12!058! 111! 1966!! <2500g!(OR!2.5)!>4500g!(OR!2.4)!
Keskinen!
et!al.!!
(2013)!
Prospective!
birth!cohort!
(Finland)!
10!526!! 150! 1966!! <2500g!!(N/A)!>4500g!!(OR!4.0)!
*!Note!that!in!the!study!by!Abel!et(al.!(2010)!the!association!between!birth!weight!and!psychotic!
disorders!in!general!was!investigated!(ICDO9!diagnoses!290O319,!ICDO10!diagnoses!F20OF29).!
SZ!=!Schizophrenia.!ASD!=!Autism!spectrum!disorder.!
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BIRTH(WEIGHT(AND(SCHIZOPHRENIA_(POTENTIAL(CAUSAL((
MECHANISMS(
Several theories on the causal mechanisms underlying the association between 
birth weight and schizophrenia risk have been put forth. The aetiological 
mechanisms associated with LBW likely differ from those associated with 
HBW. 
 
LOW(BIRTH(WEIGHT((
 
LBW has been associated with an increased risk of various medical conditions 
later in life, including coronary heart disease, stroke, hypertension and non-
insulin-dependent diabetes (Barker, 2004). The developmental origins of 
disease hypothesis, the Barker hypothesis, proposes that birth weight reflects 
maternal nutritional status during pregnancy. The hypothesis postulates that 
the foetus responds to prenatal malnutrition with permanent changes in the 
anatomy and physiology of numerous organ systems, reflected by reductions 
in cell numbers, alterations in organ structure and the resetting of hormonal 
axes (Barker et al., 1995). It has been suggested that this response is 
physiologically adaptive in preparing the organism for an environment in 
which nutrition is limited. However, when the organism later encounters an 
environment of nutritional excess the adaptive capacity of the genetically 
programmed “thrifty genotype” is limited, resulting in pathology. It has been 
suggested that the underlying processes are epigenetically driven (El Hajj et 
al., 2014).  
 
LBW has been associated with poorer pre-morbid functioning and an earlier 
at age onset of schizophrenia (Rifkin et al., 1994). Decreasing birth weight has 
also been associated with increasing cognitive impairment in the general 
population and in individuals with a SSD (Tanskanen et al., 2011; Freedman 
et al., 2013). Very low birth weight (VLBW) (< 1500 g) has been associated 
with neurocognitive outcomes, including inattention and reduced 
psychosocial functioning during adolescence (Indredavik et al., 2010). The 
association between birth weight and brain structure has also been 
investigated. Increasing birth weight has been found to associate with 
increasing cortical surface area, whereas decreasing birth weight has been 
associated with smaller total surface area, within multiple regions (Walhovd 
et al., 2012; Haukvik et al., 2014).  
 
Insulin-like factors (IGFs), in particular IGF-I and IGF-II, play a role in human 
growth and neurogenesis, and have been hypothesized to play a role in the 
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pathogenesis of schizophrenia (Gunnell and Holly, 2004). The epigenetic 
regulation of IGF-II expression has been proposed to associate with both 
cognitive functioning and birth weight (Heijmans et al., 2008; Wehkalampi et 
al., 2013; Iwamoto and Ouchi, 2014). Prenatal undernutrition (Heijmans et 
al., 2008), VLBW (Wehkalampi et al., 2013), pre-eclampsia (He et al., 2013) 
and decreased cognitive functioning (working memory) (Cordova-Palomera et 
al., 2014) have all been associated with decreased levels of IGF-II gene 
methylation. 
 
Prenatal infection and pre- and perinatal hypoxia have been associated with 
increased schizophrenia risk, particularly in combination with genetic 
susceptibility (Nicodemus et al., 2008; Clarke et al., 2009). Foetal growth 
among individuals with genetic liability for schizophrenia has been suggested 
to be particularly vulnerable to the effects of prenatal exposure to infection or 
hypoxia (Fineberg et al., 2013). Pre-eclampsia has also been reported to 
mediate the association observed between LBW and schizophrenia, suggesting 
a role for placental dysfunction in relation to LBW-associated schizophrenia 
risk (Eide et al., 2013). 
 
Exposure to stress during pregnancy has been found to activate the 
hypothalamic–pituitary–adrenal (HPA) axis, leading to increased maternal 
glucocorticoid secretion, which has been associated with decreased birth 
weight (Brown, 2011a). 
 
HIGH(BIRTH(WEIGHT((
(
HBW has been associated with increased schizophrenia risk, particularly 
among offspring presenting with increased genetic susceptibility for 
schizophrenia (Keskinen et al., 2013). Other studies have also found an 
association between HBW and schizophrenia (Hultman et al., 1997; Gunnell 
et al., 2003; Bersani et al., 2007; Moilanen et al., 2010) and ASDs (Abel et al., 
2013; Byars et al., 2014). However, several studies reporting an association 
between LBW and schizophrenia have not detected an association between 
HBW and schizophrenia (Dalman et al., 1999; Dalman et al., 2001; Abel et al., 
2010).  
 
Genetic susceptibility to schizophrenia has been suggested to increase the 
vulnerability of the neurodevelopmental process to the effects of obstetric 
complications, with respect to which the association between perinatal 
hypoxia and genetic liability represents a particularly well-established finding 
(Stefanis et al., 1999; Rosso et al., 2000; Cannon et al., 2002b; Van Erp et al., 
2002; Schulze et al., 2003; Ebner et al., 2008). Perinatal hypoxia has been 
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found to interact with variants of serine-threonine protein kinase 1 (AKT1), 
BDNF, dystrobrevin binding protein 1 (DTNBP1) and GRM3 in association 
with increased schizophrenia risk (Nicodemus et al., 2008). A variant of 
GRM3 has been found to interact with perinatal hypoxia in association with a 
reduction in hippocampal volume among offspring who develop schizophrenia 
(Haukvik et al., 2010). Genetic predisposition has been suggested to mediate 
the effect of LBW and pre- and perinatal hypoxia on school performance 
(Forsyth et al., 2012). Keskinen et al. (2013) proposed that the observed 
association between HBW and increased schizophrenia risk, in combination 
with increased genetic liability, could involve epigenetic mechanisms 
impacting the neurodevelopmental process and conferring elevated sensitivity 
to subsequent environmental insults.  
Gestational diabetes, one of the strongest triggers of HBW, has been suggested 
to be associated with increased prenatal oxidative stress, immune system 
disturbances and chronic foetal hypoxia, factors which have been suggested to 
represent potential schizophrenia-associated risk factors (Wallace and 
McEwan, 2007; Reece et al., 2009; Benros et al., 2011; Ornoy, 2011; 
Vambergue and Fajardy, 2011; Muller et al., 2015). Although an association 
between maternal diabetes and schizophrenia has been documented (Cannon 
et al., 2002a), this association has not been extensively replicated. The meta-
analysis conducted by Cannon et al. (2002a) was based on two studies in 
which an association between diabetes in pregnancy and schizophrenia risk 
among offspring was described (Jones et al., 1998; Hultman et al., 1999); 
neither study specified type of diabetes (type I vs. type II vs. gestational 
diabetes mellitus). The foundation for this association is based on the 
observation that three individuals, who were exposed to diabetes during 
pregnancy, developed schizophrenia (ntotal=237). Maternal obesity, which is 
associated with both gestational diabetes and HBW, has been associated with 
increased schizophrenia risk among offspring (Khandaker et al., 2012). 
Although the original developmental origins of disease hypothesis described 
by Barker et al. (1995) focused on the investigation of LBW in relation to future 
morbidity among offspring, HBW has also been reported to be associated with 
increased diabetes mellitus type II (T2DM) susceptibility (McCance et al., 
1994). Interestingly, T2DM has been found to be more prevalent among 
parents of individuals with non-affective psychotic disorders, suggestive of 
shared environmental or genetic risk factors (Miller et al., 2016).  Gestational 
diabetes has also been found to be associated with various HBW independent 
pre- and perinatal factors, including placental abnormalities, pre-eclampsia, 
prenatal hypoxia, decreased birth weight, lower Apgar scores, neonatal 
hypoglycaemia and Caesarean section, many of which have been 
independently associated with schizophrenia (Cannon et al., 2002a; Wadsack 
et al., 2012).  
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The mechanisms underlying the potential association between maternal 
diabetes during pregnancy and increased schizophrenia risk among offspring 
remain unsubstantiated (Cannon et al., 2002a). Maternal hyperglycaemia 
causes foetal hyperglycaemia and foetal hyperinsulinaemia, increasing foetal 
metabolism and oxygen consumption and resulting in foetal hypoxia (Cvitic et 
al., 2014). The foetus responds to hypoxia by increasing red blood cell 
production, increasing iron demand of the foetus (Teramo, 2014). Foetal 
erythropoiesis is driven by the mobilization of iron reserves from 
tissues/organs, including the brain (Petry et al., 1992), with potential 
neurodevelopmental consequences (Radlowski and Johnson, 2013), which 
from a theoretical standpoint has been postulated to elevate subsequent 
schizophrenia risk (Van Lieshout and Voruganti, 2008). Diabetes during 
pregnancy is also associated with an increase in the production of 
proinflammatory cytokines, e.g. interleukin 6 and tumour necrosis factor 
alpha (TNF-α) (Cvitic et al., 2014), which have been found to be elevated in 
psychosis (Khandaker et al., 2015). Elevated levels of proinflammatory 
cytokines during pregnancy have been associated with increased cognitive 
impairment and aberrant dopaminergic functioning among offspring (Girgis 
et al., 2014) and have thus been suggested to exhibit the potential to influence 
the neurodevelopmental process in relation to increased schizophrenia risk 
(Van Lieshout and Voruganti, 2008). Maternal diabetes during pregnancy is 
also associated with increased oxidative stress, resulting from a dysbalance 
between the levels of reactive oxygen species (ROS) and antioxidant defences 
(Shang et al., 2015). ROS have the propensity to damage DNA, protein and 
lipids, thus influencing cellular functioning. It has been proposed that the 
brain is particularly susceptible to the disruptive effects of oxygen radicals due 
to its high oxygen consumption (Van Lieshout and Voruganti, 2008).  
 
Interstingly, HBW has also been associated with an increased risk of 
immunological disorders among offspring, including systemic lupus 
erythematosus, rheumatoid arthritis and some childhood leukaemias (Simard 
et al., 2008; Caughey et al., 2009; Mandl et al., 2009).  
 
Maternal schizophrenia has been associated with increased risk of obstetric 
complications, including LBW among offspring (Jablensky et al., 2005; 
Schneid-Kofman et al., 2008). General maternal psychiatric morbidity during 
pregnancy has been associated with increased perinatal morbidity and 
mortality among offspring, and women with schizophrenia are more likely to 
receive inadequate prenatal care (Lin et al., 2009). In a study on pregnancy-
related mortality, Schneid-Kofman et al. (2008) found psychiatric patients to 
be older and to have a higher prevalence of diabetes and hypertensive 
disorders during pregnancy, associated with an elevated perinatal mortality 
rate, congenital malformations, low Apgar scores and LBW (<2500 g). 
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2.7.2.2.( POSTNATAL(RISK(FACTORS(
 
An association between urbanicity and increased schizophrenia risk has been 
described (Vassos et al. 2012). The observed association has been suggested to 
be ”dose-dependent”, in that both rising levels of urbanicity and increasing 
duration of time spent in an urban area have been proposed to be associated 
with a linear increase schizophrenia risk (Pedersen and Mortensen, 2001). 
Proposed causal factors include selective migration, social fragmentation and 
social deprivation, nutritional effects and exposure to various environmental 
factors (infections, stress, pollutants) (Pedersen and Mortensen, 2006; 
Zammit et al., 2010; Lederbogen et al., 2011; Vassos et al., 2012).  
Infection and inflammation during childhood and adolescence have been 
associated with an increased risk of psychotic disorders. Childhood CNS viral 
infections have been found to increase the risk of psychotic disorders 
(Khandaker et al., 2012). Severe bacterial infections during childhood have 
also been found to increase the risk for psychotic disorders (Blomström et al., 
2014). Possible mechanisms include both the direct effect of the pathogen, and 
the effect of the inflammatory response on the developing brain (Khandaker 
et al., 2012). Evidence suggests that autoimmune diseases may increase 
schizophrenia risk (Benros et al., 2011). An association has also been reported 
between first hospital contact due to infection and increased schizophrenia 
risk (Nielsen et al., 2014). The role of the immune system in relation to the 
pathogenesis of schizophrenia has recently gained further insight upon GWAS 
findings, implicating an association between the gene coding for complement 
component 4 and schizophrenia (Schizophrenia Genetics Consortium, 2014; 
Sekar et al., 2016). The classic complement system has been observed to 
mediate synapse elimination in a mouse model (Stevens et al., 2007).  
Various social and psychological factors during childhood, reflecting 
childhood adversity, such as loss of a parent, childhood maltreatment and 
socioeconomic adversity, have been associated with increased risk of 
schizophrenia and other psychotic disorders (Wicks et al. 2005; Brown, 2011a; 
Varese et al., 2012).  
Migration has been found to be associated with increased schizophrenia risk 
(McGrath et al., 2004, Saha et al., 2005, Fearon et al., 2006, Bourque et al., 
2011). Schizophrenia risk has been found to be elevated among both first-
generation and second-generation migrants (Bourque et al., 2011). Moreover, 
refugee migrants have been found to present with a higher risk of non-affective 
psychotic disorders than non-refugee migrants (Hollander et al., 2016). 
Several biological and social factors have been suggested to explain these 
observations, including viral infections, vitamin D deficiency, social 
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discrimination and social defeat (Cantor-Graae and Selten, 2005; Bourque et 
al., 2011).  
Cannabis use has been associated with a 2.1-fold increase in schizophrenia risk 
(Henquet et al., 2008). Cannabis has also been associated with earlier age at 
onset of psychotic disorders (Decoster et al., 2011). A dose-related effect has 
been observed, with heavy use being associated with a 3.9-fold increase in 
schizophrenia risk, in comparison to the general population (Marconi et al., 
2016).  
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2.7.3.( GENE[ENVIRONMENT(INTERACTIONS(
 
A proportion of the high heritability seen in schizophrenia has been suggested 
to be accounted for by gene-environment interactions (Howes and Murray, 
2014). A gene-environment interaction posits that the effect of a specific 
environmental exposure on disease risk is different among individuals with 
different genotypes, or that the effect of a genotype on disease risk is different 
among individuals with different environmental exposures (Ottman, 1996). 
Pre- and perinatal factors have been noted to increase schizophrenia risk, 
particularly among subjects with increased familial liability (Jablensky et al., 
2005; Clarke et al., 2009; Keskinen et al., 2013). For instance, one study found 
that the effect of prenatal exposure to pyelonephritis on psychosis risk was five 
times greater among individuals with a family history of psychosis than 
individuals without a family history (Clarke et al., 2009). Recently, the 
interaction of specific gene variants and defined environmental exposures has 
been investigated in relation to psychiatric morbidity (Caspi et al., 2002; Caspi 
et al., 2003; Dick et al., 2011; Uher, 2014), including schizophrenia risk (Caspi 
et al., 2005). Many gene-environment interactions have been described in 
relation to psychotic symptoms (Modinos et al., 2013) and can be categorized 
according to developmental phase: (1) pre- and perinatal and (2) postnatal-
premorbid.  
2.7.3.1.( PRE[(AND(PERINATAL(PERIODS(
 
Investigation of potential gene-environment interactions during the peri- and 
neonatal periods has focused on environmental exposures related to: (1) 
perinatal hypoxia (Schmidt-Kastner et al., 2012), (2) maternal infection 
during pregnancy (Demontis et al., 2011; Borglum et al., 2014) and (3) season 
of birth (Narita et al., 2000; Chotai et al., 2003) (see Table 9). 
 
Perinatal hypoxia has been found to interact with variants of AKT1, BDNF, 
DTNBP1 and GRM3 in association with increased schizophrenia risk 
(Nicodemus et al., 2008). A variant of GRM3 has been found to interact with 
perinatal hypoxia in association with a reduction in hippocampal volume 
among offspring who develop schizophrenia (Haukvik et al., 2010). 
Evidence suggests an interaction between variants of NMDA-receptor genes 
(GRIN2A and GRIN2B) and maternal Herpes Simplex Virus – type 2 (HSV-2) 
infection, denoted by seropositivity during pregnancy, in relaton to increased 
schizophrenia risk among offspring (Demontis et al., 2011). An interaction 
between the gene zinc finger E-box binding homeobox 1 (ZEB1) and maternal 
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cytomemalovirus (CMV) infection during pregnancy in relation to 
schizophrenia risk has also been reported (Borglum et al., 2014).  
 
An interaction between season of birth and genetic variants of the dopamine 
receptor 4 (DRD4) (Chotai et al., 2003), the human leukocyte antigen - 
antigen D related receptor 1 (HLA-DR1) (Narita et al., 2000) and the serotonin 
transporter-linked polymorphic region (5-HTTLPR) (Chotai et al., 2003) have 
been reported in relation to elevated schizophrenia risk. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 58 
Table(9.( PreO! and! perinatal! geneOenvironment! interactions! and! psychosis.! The!
interactions!involving!hypoxia!are!depicted!in!light!blue,!infection!during!pregnancy!in!yellow,!
and! season! of! birth! in! light! red.! Significant! /! nonsignificant! associations! are! indicated! in!
green/red.!Modification!of!the!table!presented!by!Modinos!et(al.!(2013).!!
GENE( AUTHOR(( SNP( ENVIRONMENTAL(((EXPOSURE(
OUTCOME((
VARIABLE( RESULT(
AKT1< Nicodemus!et(al.!(2008)!
rs2494735!
rs3803300!
rs1130233!!
Perinatal!hypoxia! Schizophrenia!
+!!
+!!
+!!
BDNF<
<
Nicodemus!
et(al.!(2008)!
rs2049046!!
ss76882600!! Perinatal!hypoxia! Schizophrenia!
+!!!
+!!
Haukvik!et(
al.!(2010)! ! Perinatal!hypoxia!
Hippocampal!
volume! O!
CHRNA7< Nicodemus!et(al.((2008)! ! Perinatal!hypoxia! Schizophrenia! O!
DRD4< Chotai!et(al.!(2003)! DRD4! Seasonality!of!birth! Schizophrenia!
+!
(women)!
DTNBP1<
<
Nicodemus!
et(al.!(2008)! rs875462!! Perinatal!hypoxia! Schizophrenia! +!
Haukvik!et(
al.,!(2010)! 11!SNPs! Perinatal!hypoxia!
Hippocampal!
volume! O!
GRM3<
Nicodemus!
et(al.!(2008)! rs7808623!! Perinatal!hypoxia! Schizophrenia! +!
Haukvik!et(
al.((2010)! rs13242038!! Perinatal!hypoxia!
Hippocampal!
volume!
+!!
!
HLA<<
Tochigi!et(
al.!(2002)!
HLAOA24!
HLAOA26! Seasonality!of!birth! Schizophrenia! −!
Narita!et(al.!
(2000)! HLAODR1! Seasonality!of!birth! Schizophrenia!! +!
5=
HTTLPR<
Chotai!et(al.!
(2003)! 5OHTTLPR! Seasonality!of!birth! Schizophrenia!
+!
(women)!
MTHFR<< Muntjewerff!et(al.!(2011)! rs1801133! Seasonality!of!birth! Schizophrenia! O!
NMDA< Demontis!et(al.!(2011)!
GRIN2A!!
GRIN2B!
Maternal!HSVO2!
seropositivity!during!
pregnancy!
Schizophrenia!!
!
+!!
!
NOTCH4< Nicodemus!et(al.!(2008)! ! Perinatal!hypoxia! Schizophrenia! O!
NRG1<
Nicodemus!
et(al.((2008)! ! Perinatal!hypoxia! Schizophrenia! O!
Haukvik!et(
al.!(2010)! 12!SNPs! Perinatal!hypoxia!
Hippocampal!
volume! O!
PRODH< Nicodemus!et(al.!(2008)! ! Perinatal!hypoxia! Schizophrenia! O!
RGS4< Nicodemus!et(al.!(2008)! ! Perinatal!hypoxia! Schizophrenia! O!
TNF=α< Nicodemus!et(al.!(2008)! ! Perinatal!hypoxia! Schizophrenia! O!
TPH<< Chotai!et(al.!(2003)! rs1800532! Seasonality!of!birth! Schizophrenia! O!
ZEB1< Borglum!et(al.!(2014)! rs7902091!
Maternal!CMV!
infection!during!
pregnancy!
Schizophrenia!! +!
 
AKT1! (serineOthreonine! protein! kinase),! BDNF! (brainOderived! neurotrophic! factor),! CHRNA7(
(cholinergic! receptor! nicotinic! alpha! 7! subunit),! DRD4( (dopamine! receptor! 4),! DTNBP1(
(dystrobrevin! binding! protein! 1),! GRM3! (glutamate! metabotropic! receptor! 3),! HLA! (Human!
Leukocyte! Antigen),! 5FHTTLPR! (SerotoninOtransporterOlinked! polymorphic! region),! MTHFR(
(methylenetetrahydrofolate! reductase),! NMDA! (NOmethylODOaspartate),! NOTCH4! (neurogenic!
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locus! notch! homologue! 4),! NRG1! (neuregulin! 1),! PRODH! (proline! dehydrogenase),! RGS4!
(regulator! of! GOprotein! signalling! 4),! TNFFα! (tumour! necrosis! factor! alpha),! TPH! (tryptophan!
hydroxylase),(ZEB1!(zinc!finger!EObox!binding!homeobox!1).!
 
2.7.3.2.( POSTNATAL[PREMORBID(PERIOD(
 
The most widely investigated gene-environment interactions relative to the 
postnatal-premorbid period has focused on environmental exposures related 
to: (1) cannabis use, (2) childhood trauma and (3) stressful life events (Table 
10).   
An interaction has been described between COMT Val158Met and cannabis 
use in relation to (1) psychotic experiences (Henquet et al., 2006; Henquet et 
al., 2009), (2) increased susceptibility to schizophreniform disorder (Caspi et 
al., 2005) and (3) increased symptom severity in schizophrenia (Nieman et al., 
2016). Some studies have failed to detect an interaction between COMT and 
cannabis use in psychosis (Zammit et al., 2007). COMT is involved in the 
synaptic metabolism of dopamine. The substitution of valine (Val) to 
methionine (Met) at codon 158, denoted COMT Val158Met, is the result of a 
missense G to A mutation, resulting in the translation of an enzyme, which is 
slower at breaking down dopamine (Lachman et al., 1996). Individuals 
carrying the Met/Met genotype have the lowest and Val/Val the highest 
enzymatic activity, and heterozygotes present with intermediate enzymatic 
activity (Mannistö et al., 1999). The Val/Val genotype has been associated with 
an increased risk of psychosis (Caspi et al., 2005).  
 
An interaction between AKT1 and cannabis use has been found in relation to 
increased risk of (1) psychotic experiences (Bhattacharyya et al., 2012) or 
psychosis (Di Forti et al., 2012) and (2) earlier age at onset of schizophrenia 
(Decoster et al., 2011). Some studies have failed to detect an interaction 
between AKT1 and cannabis in psychosis (Zammit et al., 2007). AKT1 is a 
protein serine/threonine kinase involved in various intracellular functions, 
including the regulation of cell-cycle progression, cell size, cell metabolism 
and cell survival (apoptosis) (Freyberg et al., 2010). It has also been found to 
be an important signalling molecule downstream of the dopamine D2 receptor 
(DRD2) (Arguello and Gogos, 2008).  
 
The interaction of receptors mediating dopamine transmission has also been 
investigated in relation to cannabis use in psychosis. The dopamine 
transporter gene (DAT1) has been found to interact with cannabis in 
association with both psychotic experiences and regional brain activation 
(Battacharyya et al., 2012). An interaction between DRD2 and cannabis use 
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has also been documented in relation to psychotic symptoms (Colizzi et al., 
2015). 
 
Evidence suggests an interaction between the cannabinoid receptor (CNR1) 
and cannabis use in relation to both reduced white matter volume and 
increased neurocognitive impairment (Ho et al., 2011). The simultaneous 
analysis of the interaction of multiple schizophrenia-associated genes, 108 loci 
identified by the Schizophrenia Genetics Consortium (2014) and cannabis use 
has revealed an interaction between polygenic risk and cannabis use in 
relation to cortical thickness, particularly among males (French et al., 2015). 
 
Variants of BDNF and childhood trauma have been found to interact, in 
association with an increase in psychotic experiences (Alemany et al., 2011). 
Aas et al. (2014) recently described an interaction between a Val66Met variant 
of BDNF and childhood trauma in relation to reduced BDNF mRNA 
concentration, reduced hippocampal volume and increased schizophrenia 
risk. 
 
Other genes, including the FK506-binding protein gene (Fk506), the forkhead 
box P2 gene (FOXP2) and the nitric oxide synthase 1 [neuronal] adaptor 
protein gene (NOSA1P), have been proposed to interact with childhood 
trauma, in relation to increased cognitive impairment in schizophrenia 
(Fk506), auditory verbal hallucinations (FOXP2) and increased schizophrenia 
risk (NOSA1P), respectively (Husted et al., 2012; McCarthy-Jones et al., 2014; 
Green et al., 2015).  
 
Several studies have reported an interaction between the COMT Val158Met 
variant and stress in relation to both increased psychotic experiences and 
symptoms (Stefanis et al., 2007; van Winkel et al., 2008; Simons et al., 2009; 
Peerbooms et al., 2012). Psychotic expreciences in relation to the interaction 
of stress and COMT Val158Met have been suggested to be modulated by a 
variant of the methylenetetrahydrofolate reductase (MTHFR) gene 
(Peerbooms et al., 2012). A variant of the neuregulin 1 (NRG1) gene has also 
been implicated to interact with psychosocial stress in relation to unusual 
thought content (Keri et al., 2009). 
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Table(10.( PostnatalOpremorbid! geneOenvironment! interactions! and! psychosis.! The!
interactions! involving!cannabis!are!depicted! in! light!green!and!childhood!trauma!/!stress! in!
grey.!Significant!/!nonsignificant!associations!are!indicated!in!green/red.!Modification!of!the!
table!presented!by!Modinos!et(al.!(2013).!
 
GENE( AUTHOR(( SNP( ENVIRONMENTAL(EXPOSURE(
OUTCOME((
VARIABLE(
RESUL
T(
AKT1<<
<<
Decoster!et(
al.!(2011)! rs6265!! Cannabis!!
Ageat!onset!of!
schizophrenia! +!
Di!Forti!et(al.!
(2012)! rs2494732!
Cannabis!(1)!
lifetime!
history!and!(2)!
frequency!of!use!
Psychotic!
disorder!
+!
+!
Bhattacharyy
a!et(al.!
(2012)!
rs1130233! Cannabis!!(deltaO9OTHC)!
Psychotic!
experiences,!
regional!brain!
activation!
+!
BDNF<
Alemany!et(
al.!(2011)! !rs6265! Childhood!abuse!
Psychotic!
experiences!
+!
+!
Aas!et(al.!
(2014)! Val66met!!! Childhood!trauma!
BDNF!mRNA,!
Hippocampal!
volume,!
Schizophrenia!
risk!
+!
CNR1<<
Zammit!et(al.!
(2007)! rs1049353! Cannabis!
Psychotic!
disorder! −!
Ho!et(al.!
(2011)! rs12720071! Cannabis!
WM!volumes!
and!
neurocognitive!
impairment!
+!
COMT<
Caspi!et(al.!
(2005)! rs4680! Cannabis!
Schizophrenifor
m!disorder! +!
Henquet!et(
al.!(2006)! rs4680!
Cannabis!
(deltaO9OTHC)!
Psychotic!
experiences! +!
Zammit!et(al.(
(2007)!
rs4680!
rs737865!!
rs165599!
Cannabis! Psychotic!disorder! −!
Henquet!et(
al.!(2009)! rs4680! Cannabis!
Psychotic!
experiences!! +!
Nieman!et(
al.!(2016)! rs4680! Cannabis!
Symptom!
severity,!
schizophrenia!
+!
Stefanis!et(
al.!(2007)! rs4680! Stress!
Psychotic!
symptoms! +!
van!Winkel!
et(al.((2008)! rs4680! Stress!!
Psychotic!
experiences!! +!
Simons!et(al.!
(2009)! rs4680! Stress!!
Feelings!of!
paranoia!! +!
Collip!et(al.!
(2011)! rs4680! Stress!!
Psychotic!
experiences!! +!
Peerbooms!
et(al.!(2012)! rs4680! Stress!!
Psychotic!
experiences!! +!
<
COMT<=<
MTHFR<<
Peerbooms!
et(al.((2012)! rs1801133! Stress!
Psychotic!
experiences!! +!
Peerbooms!
et(al.((2012)! rs1801131! Stress!
Psychotic!
experiences!! O!
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DAT1<
Bhattacharyy
a!et(al.!
(2012)!
3’UTR!VNTR!! Cannabis!!(deltaO9OTHC)!
Psychotic!
experiences!
and!regional!
brain!activation!
+!
DRD2<< Colizzi!et(al.!(2015)! rs1076560! Cannabis!!
Psychotic!
symptoms! +!
FK506<< Green!et(al.!(2015)!
rs1360780!!
rs9470080!!
rs4713902!!
rs9394309!!
Childhood!
maltreatment!
Cognition!in!
schizophrenia! +!
FOXP2<
McCarthyO
Jones!et(al.!
(2014)!
rs1456031!
Childhood!
parental!
emotional!abuse!!
Auditory!verbal!
hallucinations!
+(
!
NOSA1P<< Husted!et(al.!(2012)! !
Cumulative!
adversity!index:!
childhood!illness,!
family!instability!!
Schizophrenia! +!
NRG1<< Keri!et(al.!(2009)!
rs6994992!
rs10954867!!
rs7005288!!
Psychosocial!
stress!!
Unusual!
thoughts! +!
ST8SIA2< Mandelli!et(al.!(2016)!
rs3759917!
rs11632521!
rs3784722!
rs4777989!!
rs2290492!!
rs8035760!
rs11853992!
rs17522085!!
Stressful!life!
events!
Schizophrenia!
spectrum!
disorder!risk!
O!
POLYGENI
C(
BaniOFatemi!
et(al.((2016)! rs7897059! Childhood!trauma!
Schizophrenia!O!
suicide!attempt! !!!!!!+!
van!Winkel!
and!the!
Genetic!Risk!
Outcome!
Psychosis!
Group!
(2011)!
152!SNPs!in!
42!genes! Cannabis!
Psychotic!
disorder! +!
French!et(al.!
(2015)!
108!genes!
(Schizophreni
a!Genomic!
Consortium,!
2014)!!
Cannabis! Cortical!thickness! +!
AKT1( (serineOthreonine! protein! kinase),! BDNF( (brainOderived! neurotrophic! factor),! CNR1!
(cannabinoid! receptor! 1),! COMT! (catecholamineOOOmethylOtransfrease),! MTHFR!
(methylenetetrahydrofolate!reductase),!DAT1!(dopamine!transporter!1),!DRD2!(dopamine!receptor!
2),!FK506((FK506Obinding!protein),!FOXP2((forkhead!box!P2),!NOSA1P((nitric!oxide!synthase!1!
[neuronal]! adaptor! protein),! NRG1( (neuregulin! 1),! ST8SIA2! (ST8! alphaONOacetylOneuraminide!
alphaO2,8Osialyltransferase!2).!!
!
!
!
!
!
!
!
!
!
!
!
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2.8( TREATMENT(OF(SCHIZOPHRENIA(
 
The treatment of schizophrenia is based on the combination of antipsychotic 
medication and psychosocial rehabilitation (McGurk et al., 2007; Leucht et 
al., 2009; Dixon et al., 2010; Grant et al., 2012; Roberts et al., 2014). Up to 
60% of subjects with schizophrenia have been found to respond to 
antipsychotic medication (Sinclair and Adams, 2014), which is relatively 
effective for the treatment of positive symptoms (Leucht et al., 2009). 
However, antipsychotic medications have proven less effective for the 
treatment of negative and cognitive symptoms, the two symptom dimensions 
demonstrating the most robust associations with functional outcome (Karow 
et al., 2014; Kirkpatrick, 2014). There is some evidence to suggest that some 
specific psychosocial interventions, in combination with antipsychotic 
medication, may alleviate negative and cognitive symptoms in schizophrenia 
(Wykes et al., 2011; Jauhar et al., 2014; Roberts et al., 2014; Aleman et al., 
2016). 
In 2005, the Remission in Schizophrenia Working Group established a 
definition for symptomatic remission to be used as a clinically relevant 
treatment goal (Andreasen et al., 2005; AlAqeel and Margolese, 2012). 
Symptomatic remission was defined as follows: ”A state in which patients have 
experienced an improvement in symptoms to the extent that any of the 
remaining symptoms are of such low intensity that they no longer significantly 
interfere with behaviour and are below the threshold typically utilized in 
justifying a diagnosis of schizophrenia” (Andreasen et al., 2005). The term 
functional recovery has been used to broaden treatment goals beyond 
symptomatic remission to include the attainment of meaningful roles in the 
community (Lauronen et al., 2005; Liberman and Kopelowicz, 2006; 
Jääskeläinen et al., 2013; Valencia et al., 2015). Quality of life has also gained 
increasing attention as an important outcome measure (Karow et al., 2014). 
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3.(AIMS(OF(THE(STUDY(
The thesis investigates the relationship between birth weight and 
schizophrenia risk in a study sample with elevated genetic susceptibility for 
schizophrenia. The influence of birth weight on symptom severity and 
cognitive functioning was also assessed. Moreover, the interaction between 
birth weight and specific schizophrenia susceptibility genes involved in 
neurodevelopment was investigated. 
 
1.! In the first study, the association between birth weight and 
schizophrenia risk was investigated. The association between birth 
weight and schizophrenia risk was hypothesized to be augmented and 
thus highlighted in a cohort presenting with increased genetic loading 
for schizophrenia. Based on preliminary findings, the association 
between maternal diabetes, as a proxy for potential gestational 
diabetes, and schizophrenia risk was also investigated.  
 
2.! In the second study, the association between birth weight and symptom 
severity, separately for positive, disorganized and negative symptoms, 
in schizophrenia and other non-affective psychotic disorders was 
characterized. It was hypothesized that deviations of birth weight, both 
increasing and decreasing birth weight, would be associated with 
increasing symptom severity.  
 
3.! In the third study, an association between birth weight and cognitive 
performance was investigated among subjects with schizophrenia and 
their unaffected first-degree relatives. It was hypothesized that 
increased and decreased birth weight, relative to intermediate birth 
weight, would be associated with cognitive impairment among both 
subjects with schizophrenia and their first-degree relatives.  
 
4.! In the fourth study, an interaction between birth weight and specific 
genes of the DISC1 network, which have previously been associated 
with increased schizophrenia risk in the same cohort, was examined in 
relation to schizophrenia risk. It was hypothesized that genes of the 
DISC1 network could interact with birth weight in augmenting 
schizophrenia susceptibility.  
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4.(METHODS(
4.1.( THE(FINNISH(SCHIZOPHRENIA(FAMILY(STUDY(
SAMPLE(
The Genetic Epidemiology and Molecular Genetics of Schizophrenia in 
Finland study, hereafter called the Finnish schizophrenia family study, has 
been used for the characterization of genes associated with both schizophrenia 
risk and its clinical manifestations, including cognitive impairment and 
symptom severity (Hovatta et al., 1994; Hovatta et al., 1997; Hovatta et al., 
1999; Ekelund et al., 2000; Ekelund et al., 2001; Paunio et al., 2001; Tuulio-
Hendriksson et al., 2002; Hennah et al., 2003; Tuulio-Hendriksson et al., 
2003; Arajärvi et al., 2004; Ekelund et al., 2004; Paunio et al., 2004; Tuulio-
Hendriksson et al., 2004; Arajärvi et al., 2006; Hennah et al., 2007; Turunen 
et al., 2007; Wedenoja et al., 2008; Pietiläinen et al., 2009; Tomppo et al., 
2009).  
The collection of the study sample was initiated in 1988 by the Finnish 
National Institute of Public Health (since 2009, the National Institute for 
Health and Welfare). Affected subjects were originally ascertained using three 
nationwide registers: (1) the Finnish Hospital Discharge Register (hospital 
admissions) (maintained by the National Institute of Health and Welfare), (2) 
the Finnish Pension Register (disability pensions) (maintained by the Finnish 
Social Insurance Institution) and (3) the Finnish Medication Reimbursement 
Register (entitlement to subsidized outpatient medication) (maintained by the 
National Social Insurance Institution). The family members of affected 
individuals were subsequently identified from the Finnish Population 
Information System (PIS) (maintained by the Population Register Centre) 
(Hovatta et al., 1997; Arajärvi et al., 2004). All four registers have been 
computerized from the year 1968 onwards. Information concerning 
hospitalization was collected between 1969 and 1998, and information on both 
pensions and entitlement to free medications was gathered between 1969 and 
1991. 
Individuals born in 1940-1976, with a diagnosis of schizophrenia, 
schizoaffective disorder or schizophreniform disorder, who (1) had been 
hospitalized, (2) had received disability pension or (3) had been granted 
entitlement to subsidized antipsychotic medication were identified (Figure 2). 
Of the 33 731 subjects identified, 6079 were excluded due to lack of 
information concerning family members, leaving 27 652 probands potentially 
eligible for contact. Register diagnoses were based on different diagnostic 
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classification systems over time. Before 1987, diagnoses were based on the 
International Classification of Diseases, Eigth revision (ICD-8) (World Health 
Organization, 1967). In 1987-1995 psychiatric diagnoses in Finland were 
assigned based on the diagnostic criteria of the Diagnostic and Statistical 
Manual of Mental Disorders, third edition, text revision (DSM-III-R) 
(American Psychiatric Association, 1987). However, during this period 
psychiatric diagnoses in Finland were documentated using codes based on the 
International Classification of Diseases, Ninth revision (ICD-9) (World Health 
Organization, 1977). Since 1996, diagnoses have been based on ICD-10 (World 
Health Organization, 1993). Finnish register diagnoses regarding 
schizophrenia have generally been found to be accurate (Pakaslahti, 1987; 
Isohanni et al., 1997; Cannon et al., 1998; Mäkikyrö et al., 1998). 
First-degree family members of probands (parents and siblings) were 
identified from the PIS. The acquisition of information concerning first-degree 
relatives enabled the construction of pedigrees. The psychiatric diagnoses of 
parents and siblings were obtained from the same three health care registers 
described above with respect to probands: (1) the Hospital Discharge Register, 
(2) the Pension Register and (3) the Medication Reimbursement Register. 
Two subsamples of families, both with elevated genetic liability for 
schizophrenia, were drawn with respect to origin of birth: (1) nuclear families 
originating from an internal isolate (IS) region in northeastern Finland, 
having at least one sibling with schizophrenia and at least two grandparents 
born in the IS region (Arajärvi et al., 2004). The lifetime risk of developing 
schizophrenia in the IS region has been established to be 3.2% (Hovatta et al. 
1997). The IS region was originally founded by 36 settlers at the end of the 
17th century, and precise details of the subsequent births, deaths, marriages 
and movements of individuals in the IS have been well documented and 
archived (Hovatta et al., 1999). Genealogical links between most individuals 
with schizophrenia and corresponding family structures from the IS region 
have been traced and documented (Hovatta et al. 1999). From the rest of 
Finland, the “all Finland (AF) sample”, families with at least two siblings with 
schizophrenia were drawn (Ekelund et al., 2001; Paunio et al., 2001).  
 
Probands with a register-based diagnosis of schizophrenia, schizoaffective 
disorder or schizophreniform disorder were contacted through their treating 
physician. Permission to contact family members was requested from the 
proband. A research nurse met the probands and the family members and 
drew blood samples after the family had consented to participate in the study. 
For diagnostic assessment, medical records were collected from all mental 
health treatment contacts. The lifetime diagnoses according to DSM-IV 
(American Psychiatric Association, 1994) criteria were evaluated 
independently by two psychiatrists, who were blind to register diagnoses and 
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family structure. In case of disagreement, a third psychiatrist was assigned to 
assess the lifetime diagnosis. One of the psychiatrists completed the 
Operational Criteria Checklist (OPCRIT) based on lifetime review of 
symptoms (McGuffin et al., 1991). 
 
In the second phase of the study, all subjects from families from the IS region 
and a random sample of families from the AF sample were asked to participate 
in a clinical assessment protocol (Figure 2). All interviewers, who were 
psychiatric nurses, psychologists or residents in psychiatry, received extensive 
training in the use of the instruments. All participants gave blood samples, and 
medical records from all treatment contacts were collected from subjects with 
any known mental health care contacts. All patients provided written informed 
consent after the procedure had been explained to them. The ethics review 
board of the National Public Health Institute and the Hospital District of 
Helsinki and Uusimaa approved the study. The assessment protocol consisted 
of the following parts: 
 
-! The psychiatric diagnoses of patients and family members were re-
evaluated according to DSM-IV (American Psychiatric Association, 
1994) criteria. Both patients and their family members were 
interviewed using the Structured Clinical Interview for DSM-IV (SCID-
I and SCID-II) (First et al., 1997). The final DSM-IV consensus 
diagnoses were based on information gathered from the case records, 
the OPCRIT ratings and the SCID interviews. 
 
-! Assessment of symptom severity was performed using SAPS 
(Andreasen, 1984) and SANS (Andreasen, 1983). The interview 
included SAPS for affected individuals and SANS for both affected 
individuals and their non-affected family members. SAPS and SANS 
scores were based on the greatest lifetime symptom severity, using all 
information available, including discussions with health care personnel 
and family members. SANS and SAPS ratings were reviewed by a senior 
psychiatrist together with the interviewer.  
 
-! The level of psychological, social and occupational functioning was 
assessed using the Global Assessment of Functioning (GAF) scale 
(American Psychiatric Association, 2000). Age at illness onset was 
defined as the age at which the first contact with a health care provider 
was sought for psychiatric reasons or the age at which psychiatric 
symptoms began to cause subjective distress or impaired functioning.  
 
-! Both patients and their family members were asked to participate in a 
neuropsychological evaluation covering central cognitive functions 
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associated with schizophrenia (Heinrichs et al., 2008). The tests were 
administered in a fixed order by an experienced psychologist or a 
trained psychiatric nurse. Test scoring was performed by an 
experienced psychologist.  
 
 
 
 
 
 
 
 
 
 
Figure(2.( The! Finnish! schizophrenia! family! study! sample.! PPD! =! Primary! psychotic!
disorder.!
 
 
 
 
 
 
Hospital Discharge Register Pension Register Medication Reimbursement Register 
33 731 subjects with a schizophrenia spectrum diagnosis born between 1940-1976
The isolate sample
Families with at least one sibbling with
schizophrenia and at least two grandparents born
in the isolate region:
300  Families,  1047  Individuals
The All Finland sample
Families with at least two sibblings with
schizophrenia:
695 Families,  2292 Individuals
First degree relatives identified from the National Population Register (27 652 subjects with family information)
Diagnoses based on lifetime medical
records (DSM-IV)
240 Schizophrenia
357 PPD
Diagnoses based on lifetime medical records
(DSM-IV)
553 Schizophrenia
833 PPD
Refined of diagnoses (DSM-IV)
based on patient interviews (SCID I & II) 
and lifetime medical records
99   Schizophrenia
137 PPD
SAPS & SANS
96   Schizophrenia
130 PPD
39   Nonaffected relatives (SANS)
Refined of diagnoses (DSM-IV)
based on patient interviews (SCID I & II) 
and lifetime medical records
203 Schizophrenia
293 PPD
SAPS & SANS
198 Schizophrenia
283 PPD
262 Nonaffected relatives (SANS)
Neuropsychological tests
200 Schizophrenia
89   PPD
392 Nonaffected relatives
Neuropsychological tests
97   Schizophrenia
134  PPD
155 Nonaffected relatives
Excluded: 6079 subjects without family information
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4.1.2( PARTICIPANTS(
(
SUBJECTS(IN(STUDY(I(
(
The total study sample consisted of 1051 subjects, 484 males (46.1%) and 567 
females (53.9%), with information concerning birth weight. The mean birth 
weight of the total sample was 3430 g, with birth weight ranging from 1100 g 
to 5500 g. The average birth weight for females was 3360 g and for males 
3490 g.  
 
The sample consisted of 318 subjects with a primary psychotic disorder (PPD) 
diagnosis, which corresponded to a lifetime history of any psychotic disorder, 
excluding psychotic disorders caused by substance use or a general medical 
condition according to DSM-IV (American Psychiatric Association, 1994). 
The schizophrenia subgroup (n=197) resided within the PPD group. 
Altogether 860 subjects originated from the IS region and 191 subjects from 
the AF region. Of these subjects, 589 (56%) were interviewed using the 
Structured Clinical Interview for DSM-IV Axis I Diagnosis (SCID-CV) (First 
et al., 1996).  
 
The diagnoses of parents of probands were assigned according to the DSM-IV 
diagnostic procedure (American Psychiatric Association, 1994) or were based 
on ICD- 8, ICD-9 and ICD-10 for register based diagnoses (World Health 
Organization, 1967; World Health Organization, 1977; World Health 
Organization, 1993): ICD-10: F20*, F22*, F23*, F24*, F25*, F28*, F29*, F30*, 
F31*, F32.3*, F33.3*; ICD-9: 295*, 2961E, 2962*-2967*, 297*, 298*, 299*; 
ICD-8:  295*, 2960, 2961, 2962, 2963, 297*, 298*, 299*. 
A diagnosis of gestational diabetes was not routinely in use prior to the 1970s 
(Golden et al., 2009), and thus, a diagnosis of maternal diabetes at the time of 
data acquisition was used as a proxy for gestational diabetes. Information 
concerning maternal diabetes was obtained from both the patient interviews 
and information acquired from the Medication Reimbursement Register. 
Altogether 22 mothers (7%) of 69 offspring in the study group were assigned 
a diagnosis of maternal diabetes at the time of the interview. 
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????????????????????
?
A total of 282 PPD subjects, from 204 families, consisting of 103 females (37%) 
and 179 males (63%), with both birth weight data and information on 
symptom severity, as measured by SAPS (Andreasen, 1984) and SANS 
(Andreasen, 1983) were identified. The schizophrenia subgroup (n=178) 
resided within the PPD group. The median age of subjects at the time of 
interview was 44 years, ranging from 25 to 59 years. Of subjects included in 
the analysis, 112 (40%) originated from the IS region and 170 (60%) from the 
AF region. The median year of birth was 1956. Forty-one subjects (15%) were 
born before 1950, 157 (56%) were born between 1950 and 1960 and 84 (29%) 
were born after 1960. The mean birth weight of the sample was 3450 g (SD 
600 g), 3430 g for females and 3470 g for males. Symptom severity was greater 
among subjects with schizophrenia than among subjects presenting with other 
PPDs (Figure 3). 
 
 
 
?????????? ???????????????????????????????????????????????????????????????????????
?????????? ??? ?????????????? ???? ?? ?????????? ??? ???? ??? ???? ?????????? ????????? ??????? ????
??????????????????????????????????????????????????????
?
?
3.08
3.3
2.56
1.2
2.17
1.49
3.32
3.16
1.89
3.41
3.51
2.77
1.41
2.47
1.83
3.75
3.56
2.19
Hallucinations
Delusions
Bizzare Behaviour
Formal Thought Disorder
Affective Flattening
Alogia
Avolition/Apathy
Anhedonia/Asociality
Attention
Schizophrenia PPD
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SUBJECTS(IN(STUDY(III(
(
The following exclusion criteria was applied in the assessement of cognitive 
functioning: age >70 years, severe neurological disorder, mental retardation, 
severe somatic illness, current alcohol or substance use disorder and 
untestability due to severe symptoms. Relatives were excluded if they 
presented with a current psychiatric disorder.  
A total of 419 subjects, corresponding to 142 subjects with schizophrenia and 
277 non-affected first-degree relatives, with both data on neurocognitive 
performance and birth weight were identified. Out of all of the subjects in the 
analysis, 69% were born in a hospital, 16% were born at home with 
professional assistance and 15% were born at home without professional 
assistance. Males accounted for 97 subjects (68%) in the schizophrenia group 
and 133 subjects (48%) in the non-affected relatives group. Males were thus 
overrepresented in the schizophrenia group. The mean age at onset was 23 
years (SD 5 years). In the schizophrenia group, the mean age of subjects was 
44 years (SD 7 years), and the mean GAF score was 37 (SD 10) at the time of 
interview. In the non-affected relatives’ group, the mean age was 46 years (SD 
8 years) and the mean GAF score was 78 (SD 12) at the time of interview 
respectively. The mean birth weight of subjects in the schizophrenia group was 
3519 g (SD 609 g) and 3400 g (SD 562 g) in the non-affected relatives group.  
 
SUBJECTS(IN(STUDY(IV(
(
A total of 457 subjects, 204 females (44.6%) and 253 males (55.4%), with both 
genetic and birth weight data were identified.  The sample consisted of 142 
subjects (31.1%) with schizophrenia and 315 non-affected first-degree relatives 
(68.9%). Males accounted for 97 subjects (68.3%) in the schizophrenia group 
and 156 subjects (49.5%) in the non-affected relatives group. Males were thus 
again overrepresented in the schizophrenia group. In total, two hundred and 
thirty-eight subjects (52.1%) originated from the IS region and 219 (47.9%) 
from the AF region. Of subjects with schizophrenia, 52 (36.6%) originated 
from the IS region and 90 (63.4%) from the AF region. The mean birth weight 
in the schizophrenia and non-affected relatives groups was 3460 g (SD 620 g) 
and 3440 g (SD 570 g), respectively.  
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4.2.( BIRTH(WEIGHT(DATA(
 
The birth weight data of 1051 subjects from 315 families were obtained from 
birth records. The median year of birth was 1957. Subjects had been asked for 
permission for retrieval of birth records by letter from the year 1999 onwards. 
Information concerning place of birth was available for 591 individuals with 
birth weight data, of which 70.5% were born in hospital, 15.5% were born at 
home with professional (midwife) assistance and 14% were born at home 
without professional assistance. Those born at home without professional 
assistance but with birth weight data represented cases in which the midwife 
was alerted, but had arrived after delivery. While birth weight was documented 
in almost all cases, other information in the birth records was variable, e.g. 
birth length was not available for those born outside hospitals. Gestational age 
was unavailable for the majority of cases. Out of all the subjects who had given 
permission to collect birth records, 298 were omitted from the study for the 
following reasons: (1) 26 subjects declined to participate, (2) the birth records 
of 154 subjects were not acquired, (3) the birth records of 53 subjects did not 
contain data concerning birth weight and (4) for 2 subjects, the age at onset 
had not been recorded, a variable required for survival analysis (Study I). For 
the distribution of birth weight data in Studies I-IV, see Table 11.  
 
Table(11.( Categorical!distribution!of!birth!weight!data!in!Studies!IOIV.!
 
 
4.3.( NEUROPSYCHOLOGICAL(MEASURES(
For the assessment of cognitive functioning, parts of the Wechsler Adult 
Intelligence Scale – Revised (WAIS-R; Wechsler., 1981) and the Wechsler 
Memory Scale – Revised (WMS-R; Wechsler, 1987) were used, as well as the 
Trail Making Test (Reitan and Wolfson, 1985), the Stroop test (Golden., 1978; 
MacLeod., 1991) and the California Verbal Learning Test (CVLT; Delis et al., 
1987) (Table 12).  
 
( STUDY(I((
N(%)(
STUDY(II(((
N(%)(
STUDY(III(
N(%)(
STUDY(IV(
N(%)(
<2500!g! 52!(5)! 15!(5)! 16!(4)! 22!(5)!!!!!!!!!!!!!!!!!!!!!!!
2500–2999g! 167!(16)! 44!(16)! 49!(12)!! 71!(16)!
3000–4000g!! 703!(67)! 183!(65)! 294!(70)!! 307!(67)!
>4000!g! 129!(12)! 40!(14)! 60!(14)!! 57!(12)!
N(TOTAL)( 1051( 282( 419( 457(
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Table(12.( Neuropsychological!tests!used!in!the!study.!
Verbal(ability(and(
visuospatial(reasoning(
WAISOR!Vocabulary!!
WAISOR!Similarities!!
WAISOR!Block!Design!!
Processing(speed(and(
executive(functions(
WAISOR!Digit!Symbol!!
Trail!Making!part!A!!
Trail!Making!part!B!!
Stroop!Interference!!
!
Attention(and(working(
memory(
WMSOR!Digit!Span!Forward!!
WMSOR!Digit!Span!Backward!!
WMSOR!Visual!Span!Forward!!
WMSOR!Visual!Span!Backward!!
!
Verbal(learning(
(
CVLT!Immediate!recall!!
CVLT!Short!delay!recall!!
CVLT!Long!delay!recall!!
!
 
 
 
 
4.4.( GENOTYPES(
 
Twenty genetic markers, representing SNPs or haplotypes, covering five genes 
(DISC1, NDE1, NDEL1, PDE4B, PDE4D) of the DISC1 network, which had 
previously demonstrated significant association with schizophrenia risk in the 
cohort, were evaluated for analysis (Hennah et al., 2003; Ekelund et al., 2004; 
Hennah et al., 2007; Tomppo et al., 2009). Due to the limited size of the study 
sample in Study IV, comprising 457 subjects with both genetic and birth 
weight data, an allele frequency threshold was used to ensure the statistical 
feasibility of the interaction model. The threshold frequency for minor allele 
homozygotes was set at >10%. Of the 20 markers, seven met this criterion: five 
variants of the NDE1 gene (NDE1 haplotype, rs4781678, rs2242549, 
rs881803, rs2075512) and one variant of both PDE4B (rs7412571) and PDE4D 
(PDE4D haplotype) genes. The NDE1 haplotype, corresponding to a specific 
CGCC allele, comprised of the combination of the following individual NDE1 
SNPs: rs4781678, rs2242549, rs881803 and rs2075512. 
 
 
 
 
 
 74 
4.5.( STATISTICAL(ANALYSIS(
(
STUDY(I(
(
A multivariate COX frailty model was used to investigate the association 
between both (1) birth weight and (2) maternal diabetes in relation to 
subsequent schizophrenia/PPD risk among offspring (Therneau and Lumley, 
2008). Birth weight (<2500 g, 2500–2999 g, 3000–4000 g, >4000 g), 
maternal/paternal history of any psychotic illness and sex were used as 
explanatory variables in the evaluation of the association between birth weight 
and schizophrenia risk. Birth weight (<2500 g, 2500–2999 g, 3000–4000 g), 
sex and maternal diabetes were used as explanatory variables in the 
investigation of the association between maternal diabetes and schizophrenia 
risk. Family unit defined frailty, and stratification of subjects with respect to 
both temporal (decade of birth) and regional (IS region vs. AF sample) 
considerations was applied in both analyses. 
 
 
STUDY(II(
(
A General Estimating Equation (GEE) model (Liang and Zeger, 1986) was 
used to characterize the relationship between birth weight and symptom 
severity among subjects who later developed schizophrenia and a PPD 
spectrum diagnosis. Birth weight and symptom severity were investigated as 
continuous variables. The data were adjusted for sex, region of birth (IS vs. 
AF) and decade of birth (subjects born in or before the year 1960 vs. subjects 
born later than 1960). A quadratic polynomial regression model was applied 
to detect a possible non-linear relationship between birth weight and symptom 
severity. Nested models with and without a quadratic effect were evaluated 
using the Wald test to ascertain the best-fitting model. Statistical analyses 
were conducted using the R-program version 2.12.1 (R Development Core 
Team, 2010). A probability level of p<0.05 was considered significant. 
 
 
STUDY(III(
(
A GEE model (Liang and Zeger, 1986), using birth weight as a continuous 
variable, was used to investigate the association between birth weight and 
cognitive functioning among both subjects with schizophrenia and their non-
affected relatives. Place/type of delivery (i.e. hospital delivery, home delivery 
with professional assistance, home delivery without professional assistance), 
GAF (American Psychiatric Association, 2000), number of affected siblings 
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per family, place of birth (IS vs. AF), age and sex were controlled for in the 
model. A statistically significant quadratic term, indicative of a quadratic 
effect, was postulated to be suggestive of a curvilinear association between 
birth weight and cognitive functioning. The interaction between the observed 
group-specific associations was investigated to determine whether the 
observed influence of birth weight on cognitive functioning was different with 
regard to the schizophrenia and the non-affected relative groups. The effect 
sizes of the mean differences between the schizophrenia and the relatives 
group were measured using Cohen’s d (Cohen, 1988), in which effect sizes 
were denoted as small (>0.20), medium (>0.50) and large (>0.80). A 
probability level of p<0.05 was considered significant. Analyses were 
conducted using the statistical program Stata (StataCorp, Version 9.2, College 
Station, Texas).  
 
STUDY(IV(
(
A GEE model was used to test for gene environment interactions between birth 
weight and specific genes variants in relation to schizophrenia risk (Liang and 
Zeger, 1986). Explanatory variables included (1) birth weight (categorically 
divided into ≤4000!g vs. >4000!g), (2) genotype and (3) the interaction of 
birth weight and genotype. An additive genetic effect was presumed in the 
model. Place of birth (IS vs. AF) and sex were adjusted for in the model. 
Correction for multiple testing was performed and the level of statistical 
significance was set at p=0.017 (0.05/3) in view of the fact that three genes, 
which met the imposed allele frequency criteria were taken forward for 
analysis. Fisher's exact test was used to pinpoint the suggested genotype-
phenotype pairings driving the observed interactions. Analyses were 
performed using the R-program version 3.0.2 (R Development Core Team, 
2013). 
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5.(RESULTS(
5.1.( BIRTH(WEIGHT(AND(SCHIZOPHRENIA(RISK((
 
BIRTH(WEIGHT(AND(SCHIZOPHRENIA(
(
HBW (> 4000 g) was associated with a 1.68-fold increased risk of developing 
schizophrenia (Table 13). An association between HBW and PPD was not 
observed. An association between LBW (< 2500 g) in relation to both 
schizophrenia and PPD risk was not observed. Intermediate birth weight 
(3000-4000 g) was used as a reference. 
 
 
Table(13.( Hazard! Rate! Ratios! (HRRs)! of! the! association! between! birth! weight! and!
schizophrenia! risk,! in!which!birth!weight! (<2500!g,! 2500–2999!g,! 3000–4000!g,!>4000!g),!
maternal/paternal!history!of!any!psychotic!illness!and!sex!were!used!as!explanatory!variables.!
( ( HRR( 95%CI( p(
HBW!(>4000g)! SZ! 1.68! 1.13O2.50! 0.010!
PPD! 1.18! 0.84–1.65! 0.35!
LBW!(<2500g)! SZ! 1.00! 0.47–2.17! 0.99!
PPD! 0.95! 0.53–1.71! 0.87!
(
 
GESTATIONAL(DIABETES(AND(SCHIZOPHRENIA(
(
It was postulated that the association between HBW and schizophrenia could 
be driven by gestational diabetes. The association between maternal diabetes 
at the time of data collection, a proxy for gestational diabetes, was evaluated in 
relation to schizophrenia susceptibility among offspring. A statistically 
significant increase in schizophrenia risk was observed among offspring of 
mothers who developed diabetes (HRR 1.66, 95%CI 1.01-2.72, p=0.044). An 
association between maternal diabetes and psychotic disorders other than 
schizophrenia was not observed (HRR 1.48, 95%CI 0.66-3.31, p=0.34). A 
direct association between maternal diabetes and HBW was not observed.  
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5.2.( BIRTH(WEIGHT(AND(SYMPTOM(SEVERITY((
 
Both increasing and decreasing birth weight, in relation to intermediate birth 
weight, were found to be associated with increasing severity of both 
disorganized and negative symptoms. Symptoms of reality distortion 
(hallucinations, delusions) were not found to associate with birth weight. 
Decreasing birth weight was correlated with greater symptom severity than 
increasing birth weight in all of the statistically significant associations 
observed.  
Birth weight and disorganized symptoms. A U-shaped association was 
observed between birth weight and bizarre behaviour in both schizophrenia 
and PPD subjects (Table 14). A linear association was observed between birth 
weight and formal thought disorder, with lower birth weight correlating with 
greater symptom severity, among both subjects with schizophrenia and PPD.  
 
Birth weight and negative symptoms. A U-shaped association was observed 
between birth weight and both affective flattening and attentional impairment 
among subjects with PPD (Table 14). An association between birth weight and 
affective flattening was not observed in the schizophrenia group. The 
association between birth weight and attentional impairment was of 
borderline statistical significance in the schizophrenia group. A statistically 
significant association was not observed between birth weight and alogia, 
avolition–apathy and anhedonia–asociality. 
 
Table(14.( Significant! associations! observed! between! birth! weight! and! symptom!
dimensions!(SAPS/SANS!scores)!in!relation!to!both!schizophrenia!and!PPD!groups.!FTD!=!
Formal!thought!disorder.!SZ!=!Schizophrenia.!PPD!=!Primary!psychotic!disorder.!
 
Symptom(( Trend(of(
association(
Group(
(
βLinear,(((
βQuadratic(
SE( P(
Bizarre!
behaviour!
UOShaped! PPD!!
!
βLinear ! !!O
3.92!
0.76! <0.001!
βQuadratic!! 0.57! 0.12! <0.001!
SZ!
!
βLinear ! O3.14! 1.13! 0.01!
βQuadratic!! 0.44! 0.17! 0.01!
FTD! Linear! PPD!! βLinear ! 0.29! 0.12! 0.02!
SZ! βLinear ! O0.28! 0.14! 0.04!
Affective!
flattening!
UOShaped! PPD!! βLinear ! 1.87! 0.67! 0.01!
βQuadratic!! 0.26! 0.10! 0.01!
Attentional!
impairment!
UOShaped! PPD!! βLinear ! 2.72! 0.90! <0.001!
βQuadratic!! 0.36! 0.14! 0.01!
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5.3.( BIRTH(WEIGHT(AND(COGNITIVE(IMPAIRMENT((
 
A statistically significant curvilinear association was observed between birth 
weight and cognitive performance with respect to the Block Design subtest, the 
Digit Symbol subtest, the Trail Making Test parts A and B, the Digit Span 
Backward test and the Visual Span Backward test among subjects with 
schizophrenia and their unaffected first-degree relatives. Birth weight in the 
range of 3500–4000 g was associated with the highest test performance. The 
group × birth weight interactions and the group x birth weight-squared 
(group=subjects with schizophrenia vs. non-affected relatives) were not found 
to be statistically significant. See Figure 4 for a graphic illustration of the 
association between birth weight and cognitive functioning (Similarities test) 
relative to both subjects with schizophrenia and their unaffected relatives.  
 
 
Figure(4.( Predicted!Similarities!test!scores!by!birth!weight!(kg)!with!respect!to!both!(a)!
the!firstOdegree!relatives!group!(red)!and!(b)!the!schizophrenia!group!(black).!!
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5.4.( INTERACTION(OF(BIRTH(WEIGHT(AND(GENES
(((OF(THE(DISC1(NETWORK((
 
HBW was found to interact with the NDE1 haplotype (b=1.26, SE=0.5, 
p=0.012) and one of its constituent SNPs, rs4781678 (b=1.33, SE=0.51, 
p=0.010), in association with increased schizophrenia risk (Table 15). An 
interaction between birth weight and the other investigated gene variants, 
which met the imposed allele frequency threshold criteria (PDE4B, PDE4D), 
in relation to schizophrenia risk was not detected. In order to further 
characterize the genetic mechanism (major allele homozygous vs. 
heterozygous vs. minor allele homozygous) underlying the observed 
interaction, schizophrenia risk was analysed individually with respect to NDE1 
variants using the Fisher’s exact test. A significant association was observed 
between HBW and schizophrenia among minor allele homozygotes of the 
NDE1 haplotype (Figure 5) and two of its constituent SNPs, rs4781678 and 
rs2075512. This finding suggests that a recessive genetic model was driving the 
interaction. 
 
 
 
 
 
Table(15.( Interaction!between!birth!weight!(≤4000!g!vs.!>4000!g)!and!variants!of!NDE1,!
fulfilling!the!imposed!allele!frequency!criteria,!in!relation!to!schizophrenia!risk.!The!threshold!
frequency!for!minor!allele!homozygotes!was!set!at!>10%.!
!
!
NDE1(Variant( HBW(x(NDE1(Variant<
< b< SE< p<
NDE1!haplotype! 1.26! 0.5! 0.012*!
rs4781678! 1.33! 0.51! 0.010*!
rs881803! 1.07! 0.53! 0.043!
rs2075512! 1.29! 0.61! 0.035!
!
*!p<0.017!
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Figure(5.( Association!between! increasing!allele! frequency!of! the!NDE1!haplotype!and!
birth!weight!>4000!g!(dark!blue)!and!<4000!g!(light!blue)!in!relation!to!schizophrenia!risk.!!
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6.(DISCUSSION(
The main aim of the thesis was to investigate whether deviations in birth 
weight, a proxy for pre- and perinatal environmental adversity, could in 
combination with elevated genetic liability augment schizophrenia risk, and 
impact both the clinical presentation and cognitive functioning of subjects who 
develop schizophrenia. The interaction between birth weight and specific 
genes involved in neurodevelopment were also analysed. 
6.1.( BIRTH(WEIGHT(AND(SCHIZOPHRENIA(RISK((
In the first study, HBW (> 4000 g) was found to be associated with increased 
risk of schizophrenia. A statistically significant association between birth 
weight and PPDs other than schizophrenia was not detected, suggesting that 
individuals who later develop schizophrenia may be particularly sensitive to 
pre- and perinatal factors associated with birth weight. An association 
between LBW (< 2500 g) and schizophrenia was not detected, despite this 
being a widely replicated finding in the literature (Cannon et al. 2002a; Abel 
et al., 2010; Byars et al., 2014). This discrepancy is proposed to reflect the 
assumption that the risk factors associated with schizophrenia may be 
different among individuals presenting with elevated genetic liability for 
schizophrenia, in comparison to the risk factors operating in the general 
population (Keskinen et al., 2013).  It is also possible that morbidity later in 
life, which has been commonly associated with LBW, has become more 
apparent in more recent cohorts due the decrease in mortality seen among 
LBW neonates in younger cohorts as a result of advances in obstetric and 
neonatal care (McCormick et al., 1985; Heinonen et al., 1988; Sipilä et al., 
1994). The median year of the birth study sample was 1957 and thus, subjects 
comprising the study group were born during a period of major advancements 
in obstetric services in Finland. This is, for example, reflected in the number 
of births that took place in hospitals, which in Finland increased from 31.0% 
to 92.5% between the years 1940 and 1960 (Hemminki, 1983); during this 
period the infant mortality rate also decreased from 4% (1950-1951) to 0.5% 
(1991-1995) (The official statistics of Finland XI: 62, 1962; Hemminki, 1983; 
Piekkala et al., 1986; Pitkänen et al., 2000). The distribution of birth weight 
has also changed in the Finnish population, and the overall prevalence of 
HBW neonates in younger cohorts has increased (Kinnunen et al., 2003; 
Lahti-Koski et al., 2010).   
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The association between HBW and schizophrenia described in the present 
study in conjunction with elevated genetic loading for schizophrenia supports 
recent findings from the NFBC suggesting that HBW increases schizophrenia 
risk, particularly among subjects presenting with elevated genetic liability for 
schizophrenia (Keskinen et al., 2013). Interestingly, in the literature HBW has 
been found to associate with an increased risk of neurodevelopmental 
disorders, including ASDs in both the Swedish (Abel et al., 2013), and the 
Danish (Byars et al., 2014) populations. ASDs have been associated with 
elevated heritability estimates (80%) similar to that of schizophrenia (Sullivan 
et al., 2012), supporting evidence suggesting that the interaction of genetic 
predisposition and pre- and perinatal factors associated with HBW may 
influence neurodevelopment.   
This study corroborates previous reports describing an association between 
HBW and increased schizophrenia risk (Hultman et al., 1997; Gunnell et al., 
2003; Bersani et al., 2007; Moilanen et al., 2010). However, it was not possible 
to assess the direct causal factors underlying this association in the study 
sample. The causal mechanisms underlying the association between HBW and 
schizophrenia risk have not to date been investigated in the literature. One of 
the potential causal mechanisms underlying the association between HBW 
and schizophrenia could be pre- and perinatal hypoxia. HBW is associated 
with hypoxia-related obstetric complications, including prolonged labour, 
instrumental vaginal delivery, emergency Caesarean section, Apgar score <4 
and increased admission to a neonatal special care unit (Jolly et al., 2003; 
Jastrow et al., 2010). There is evidence for an association between the overall 
severity of obstetric complications and increased ventricular enlargement in 
subjects with schizophrenia (Bersani et al., 2009), and hypoxic-ischaemia-
related obstetric complications have been associated with an increased risk of 
developing a psychotic disorder (Zornberg et al., 2000). Some evidence 
suggests that subjects with genetic liability for schizophrenia, may be more 
susceptible to decreased foetal growth in connection with prenatal adversities 
such as pre-eclampsia, prenatal infection and hypoxia (Eide et al., 2013; 
Fineberg et al., 2013). An association between LBW and schizophrenia was not 
detected in this study sample, presenting with high genetic loading for 
schizophrenia, suggesting the pre- and perinatal factors associated with 
elevated genetic susceptibility may be different from those operating in the 
general population.  
The association of perinatal hypoxia and genetic liability is a well replicated 
finding in relation to schizophrenia risk (Stefanis et al., 1999; Rosso et al., 
2000; Cannon et al., 2002b; Van Erp et al., 2002; Schulze et al., 2003; Ebner 
et al., 2008). It is possible that the influence of HBW on hypoxia-related 
perinatal morbidity may have been greater in older cohorts, where access to 
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specialized obstetric and neonatal care was limited. Advances in obstetric care 
may have reduced the frequency and severity of HBW-associated hypoxia-
related obstetric complications in younger cohorts (Henriksen, 2008; 
Koyanagi et al., 2013). It is also probable that the risk of hypoxia-related 
perinatal complications associated with the delivery of a large infant would 
have been elevated, particularly among subjects born at home relative to 
subjects born in a hospital setting.  
 
Based on the primary finding of an association between HBW and 
schizophrenia, it was investigated whether this association was driven by 
maternal diabetes. Gestational diabetes, one of the strongest triggers of HBW 
(Wallace and McEwan, 2007), was not routinely diagnosed prior to the 1970s 
(Golden et al., 2009), thus information on maternal diabetes at the time of the 
interview was used a proxy for a possible history of gestational diabetes. This 
inference was justified based on findings demonstrating that women with 
gestational diabetes have been found to present with a 10-fold increased risk 
of developing T2DM (Shen et al., 2016). In the present study, maternal 
diabetes was found to increase schizophrenia risk among offspring. However, 
the association was found to be independent of birth weight. A statistically 
significant association between maternal diabetes and primary PPDs other 
than schizophrenia was not detected, suggesting that individuals who develop 
schizophrenia may be sensitive to factors related to impaired maternal glucose 
metabolism during pregnancy. The observation is in accordance with previous 
findings describing an association between maternal diabetes during 
pregnancy and increased schizophrenia risk among offspring (Cannon et al., 
2002a). However, the meta-analysis by Cannon et al. (2002a) did not 
differentiate between types of diabetes (type 1, type 2 or gestational diabetes) 
and also did not specify whether impaired maternal glucose metabolism was 
present before pregnancy. In the current study, the precise nature and course 
of maternal diabetes in relation to pregnancy were also unknown. Offspring of 
diabetic mothers have been found to present with HBW, LBW and normal 
birth weight, depending on the severity of diabetes, the degree of diabetic 
control and the presence of other complicating factors (Ornoy, 2011). Maternal 
diabetes during pregnancy is most commonly associated with HBW. However, 
diabetes during pregnancy in combination with such complications as 
nefropathy is typically associated with LBW (Kendrick et al., 2015). Diabetes 
during pregnancy is associated with foetal hypoxia, immune system activation, 
oxidative stress, placental abnormalities, pre-eclampsia, lower Apgar scores 
and increased requirement of Caesarean section, factors also associated with 
increased schizophrenia risk (Kotlicka-Antczak et al., 2001; Cannon et al., 
2002a; Van Lieshout and Voruganti, 2008; Reece et al., 2009; Benros et al., 
2011; Ornoy, 2011; Vambergue and Fajardy, 2011; Wadsack et al., 2012; Eide 
et al., 2013). These factors commonly co-precipitate and are thus not 
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independent of one another. Interestingly, T2DM has been found to be more 
prevalent among parents of individuals with psychotic disorders, suggestive of 
shared environmental and genetic risk factors underlying both disorders 
(Fernandez-Egea et al., 2008a, Fernandez- Egea et al., 2008b; Van Welie et 
al., 2013; Miller et al., 2016). Interestingly, specific variants of the D2-receptor 
gene have recently been found to associate with elevated glucose levels among 
subjects with schizophrenia, strengthening the evidence for possible shared 
risk factors underlying glucose metabolism and psychiatric morbidity 
(Lawford et al., 2016). 
Various autoimmune diseases, including systemic lupus erythematosus, 
Sjogren’s syndrome and rheumatoid arthritis, and some childhood leukaemias 
have been associated HBW (Simard et al., 2008; Caughey et al., 2009; Mandl 
et al., 2009). The mechanisms underlying an association between HBW and 
immunological disorders remain relatively unsubstantiated. One explanation 
has been suggested to relate to the effects of cortisol and prenatal 
dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis (Phillips et 
al., 1998). Patients with rheumatoid arthritis have been proposed to present 
with abnormally low levels of cortisol, which may associate with increased 
inflammation (Imrich and Rovensky, 2010).  
6.2.( BIRTH(WEIGHT(AND(SYMPTOM(SEVERITY((
In this study both low and high birth weight were associated with increased 
symptom severity, particularly with respect to disorganized and negative 
symptom dimensions, among subjects diagnosed with a PPD diagnosis, with 
elevated genetic loading for schizophrenia. These findings are in line with 
previous reports describing an association between the increasing severity of 
obstetric complications and the increasing severity of both positive and 
negative symptoms in schizophrenia (Kotlicka-Antczak et al., 2001; Guerra et 
al., 2002; Ruiz-Veguilla et al., 2008), suggesting that the pre- and perinatal 
environmental factors mediating the association between birth weight and 
schizophrenia risk may also influence symptom severity.  
 
In the study a U-shaped relationship between both increasing and decreasing 
birth weight and increasing symptom severity was described with respect to 
bizarre behaviour, affect flattening, alogia and attentional difficulties. 
Whereas, a linear association was observed between decreasing birth weight 
and increasing symptom severity of positive formal thought disorder. 
Interestingly, ASDs, which have also been associated with increasing birth 
weight (Abel et al., 2013; Byars et al., 2014), have been commonly found to 
present with symptoms resembling disorganized and negative symptoms 
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(Konstantareas and Hewitt, 2001). One of the central findings of the study was 
that birth weight was not associated with symptoms of reality distortion, in 
line with the hypothesis presented by some authors, suggesting that symptoms 
of reality distortion represent a more distal phenotypic characteristic of SSDs 
relative to disorganized and negative symptoms, which have been proposed to 
correlate more strongly with both neurodevelopment (Tsuang et al., 2000; 
Andreasen, 1999) and outcome measures, including social and functional 
impairment (Eslami et al., 2011; Moskowitz and Heim, 2011; Fulford et al., 
2013).  
 
Relatively few studies to date have investigated the relationship between the 
severity of obstetric complications in relation to symptom severity in 
schizophrenia. Individuals with a history of obstetric complications (as 
measured by APGAR score) have been reported to present with more 
prominent negative symptoms (Kotlicka-Antczak et al., 2001; Ruiz-Veguilla et 
al., 2008). In addition, Gallagher et al. (2014) found this association in female 
patients, but not in male patients. The mechanisms underlying the association 
have been suggested to be related to perinatal hypoxia. Maternal smoking 
during pregnancy, which may cause chronic foetal hypoxia, has been reported 
to be associated with a greater severity of negative symptoms in schizophrenia 
(Stathopoulou et al., 2013). Earlier age at onset of psychotic symptoms, related 
to poorer prognosis, has also been associated with perinatal hypoxia (Verdoux 
et al., 1997). However, the association between obstetric complications and 
negative symptoms may also be related to sociodemographic factors, including 
lower social class (Jones et al., 2011).  
 
The results of the study appear to support the view that the pre- and perinatal 
factors associated with both decreasing and increasing birth weight are 
associated with the severity of negative and disorganized symptoms in SSDs. 
The postulated biological mechanisms underlying the association may be 
linked to processes affecting neurodevelopment and cognition, and in this 
respect may partly overlap with the in utero environmental factors involved in 
the pathogenesis of ASDs. 
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6.3.( BIRTH(WEIGHT(AND(COGNITIVE(IMPAIRMENT((
Disorganized and negative symptoms, as compared with symptoms of reality 
distortion, have been associated with greater cognitive impairment 
(Jablensky, 2006; Ventura et al., 2010). In the study, both decreasing and 
increasing birth weight was associated with a small, but significant decrease in 
visuospatial reasoning, processing speed, set-shifting and verbal and visual 
working memory, with intermediate birth weight being associated with the 
highest cognitive performance. Our observation is in line with previous 
findings describing an association between decreasing birth weight and 
increasing cognitive impairment in SSDs (Rifkin et al., 1994; Hultman et al., 
1999; Freedman et al., 2013). These findings are also consistent with reports 
describing an association between decreasing birth weight and poorer 
cognitive functioning in the general population (Seidman et al., 2000; Taylor 
et al., 2000; Bergvall et al., 2006; Tanskanen et al., 2011). Although research 
has predominantly described an association between LBW and cognitive 
functioning, particularly in relation to the VLBW range (<1500 g) (Bohm et 
al., 2004; Murray et al., 2014; Aanes et al., 2015), HBW has also been 
associated with an increased risk of neurocognitive outcomes, including 
externalizing symptoms and social problems in adolescents and also an 
increased risk of ASDs (Shenkin et al., 2004; Leonard et al., 2008; Alati et al., 
2009; Buschgens et al., 2009; Van Lieshout and Boyle, 2011; Abel et al., 2013; 
Byars et al., 2014). Some studies have also reported an association between 
HBW and increased cognitive impairment in the general population (Sorensen 
et al., 1997; Silva et al., 2006).  
The intrauterine environment has been proposed to influence cognitive 
functioning. Evidence suggests that maternal metabolic factors, including 
increased maternal body mass index (Jones et al., 1998; Schaefer et al., 2000; 
Kawai et al., 2004; Khandaker et al., 2012), maternal hypertension (Sorensen 
et al., 2003) and pre-eclampsia (Dalman et al., 1999; Eide et al., 2013), 
influence foetal growth and increase schizophrenia risk. Structural brain 
imaging findings of healthy individuals have reported an association between 
decreasing birth weight and a decrease in regional brain surface area 
(Walhovd et al., 2012; Muller et al., 2014). Prenatal factors such as 
undernutrition, maternal cardiovascular risk factors and HPA-axis 
dysregulation, have been associated with both lower birth weight and cognitive 
outcomes among offspring (De Rooij et al., 2010; Räikkonen et al., 2012). 
Epigenetic processes are speculated to be an important mechanism by which 
the prenatal environment alters factors related to long-term health, including 
cognitive functioning (Warner and Ozzane, 2010; Eriksson, 2016). The 
epigenetic regulation of the expression of specific genes e.g. IGFs, in particular 
IGF-II, may play a role in the association between birth weight, 
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neurodevelopment and cognitive functioning (Heijmans et al., 2008; 
Wehkalampi et al., 2013; Iwamoto and Ouchi, 2014). Lower methylation of the 
IGF-II gene has been associated with prenatal undernutrition (Heijmans et al., 
2008), VLBW (Wehkalampi et al., 2013), and cognitive functioning (working 
memory) (Cordova-Palomera et al., 2014). However, socioeconomic factors 
have also been suggested to confound some of the reported associations 
between birth weight and cognitive functioning (Wong and Edwards, 2013).  
Only a few studies to date have investigated the relationship between HBW 
and cognitive functioning. It is plausible that the mechanisms underlying the 
observed association between HBW and cognitive impairment may be related 
to factors associated with perinatal hypoxia, which has also been associated 
with cognitive impairment in the general population (Anastario et al., 2012). 
Lower five-minute APGAR scores, although not a direct indicator of perinatal 
hypoxia, have been associated with cognitive impairment in the general 
population (Odd et al., 2008; Ehrenstein, 2009; Stuart et al., 2011; Tweed et 
al., 2016).  Maternal diabetes during pregnancy has also been associated with 
cognitive impairment among offspring (Silverman et al., 1998; Dahlquist et 
al., 2007; Dionne et al., 2008; Nielsen et al., 2010; Perna et al., 2015; Adane 
et al., 2016; Bytoft et al., 2016). Maternal pre-pregnancy obesity, maternal 
weight gain during pregnancy and maternal diabetes have been reported to be 
associated with dysregulation of the immune system (increased production of 
pro-inflammatory cytokines), oxidative stress, endocrinological factors 
(impacting cortisol, oestrogen and insulin levels) and nutritional factors 
(increased glucose concentration, folate deficiency), which may potentially 
impact neurodevelopment and increase the risk of ASDs and SSDs in offspring 
(Challier et al., 2008; Freeman, 2010; Van Lieshout and Boyle, 2011; Gardner 
et al., 2015).  
6.4.( INTERACTION(BETWEEN(HBW(AND(NDE1((
Evidence suggestive of a gene-environment interaction was detected between 
the NDE1 gene and HBW (> 4000 g) in association with increasing 
schizophrenia risk. The observation corroborates previous findings describing 
an association between mutations in the NDE1 gene and neurodevelopmental 
outcomes, including congenital microencephaly (Bakircioglu et al., 2011; 
Paciorkowski et al., 2013), and describing a role for NDE1 in the 
neurodevelopmental trajectory of schizophrenia (Hennah et al., 2007). The 
results also concur with previous reports describing an interaction between 
schizophrenia susceptibility genes and pre- and perinatal environmental 
factors, e.g. foetal hypoxia, with a subsequent increase in schizophrenia risk 
(Narita et al., 2000; Chotai et al., 2003; Demontis et al., 2011; Schmidt-
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Kastner et al., 2012; Borglum et al., 2014). Furthermore, the observation 
supports previous findings suggesting that the association of HBW and 
schizophrenia may be moderated by genetic predisposition (Keskinen et al., 
2013).  
 
A recent large GWAS failed to detect an association between DISC1-associated 
genes and schizophrenia (Schizophrenia Genomics Consortium, 2014). 
However, evidence suggests that the DISC1 network may be associated with 
intermediate neurocognitive phenotypes of schizophrenia and other 
psychiatric disorders (Hennah et al., 2005; Carless et al., 2011). Duplications 
and deletions at the 16p13.11 locus have been found to predispose to various 
neurodevelopmental disorders, including ASDs, attention deficit disorder, 
intellectual disability and schizophrenia (Tropeano et al., 2013). Large 
alterations of the gene NDE1, a DISC1 binding partner located within the 
16p13.11 locus, have been implicated in the disruption of the 
neurodevelopmental process, and smaller alterations (variants) of the gene 
have been associated with increased schizophrenia susceptibility (Bradshaw, 
2016). The interaction of HBW and NDE1, both of which have previously been 
identified as independent risk factors of neurodevelopmental outcomes (Abel 
et al., 2013; Byars et al., 2014; Bradshaw, 2016), from a hypothesis-driven 
perspective reflects a biologically plausible aetiological mechanism with 
regard to the neurodevelopmental trajectory of schizophrenia. An association 
between NDE1 and HBW has not previously been reported, and the finding 
thus needs to be replicated.  
!
The molecular mechanisms underlying the observed interaction may be 
related to foetal hypoxia, which has been found to interact with variants of 
AKT1, BDNF, DTNBP1 and GRM3 in association with increased schizophrenia 
risk (Nicodemus et al., 2008). Although a direct association between foetal 
hypoxia and NDE1 functioning has not yet been described, evidence suggests 
that the half-life of its binding partner DISC1 is decreased (degradation of 
DISC1 is increased) under hypoxic conditions (Barodia et al., 2015). Variants 
of NDE1, in relation to the concerted functions of the DISC1 network, may 
possibly be susceptible to HBW-associated perinatal hypoxia, impacting 
neurodevelopment and influencing subsequent schizophrenia risk.   
 
 
 
 
 
 
 89 
6.5.( STRENGTHS(AND(LIMITATIONS(OF(THE(STUDY(
General strengths of the study include the reliability of diagnostic data and the 
fact that information concerning birth weight was obtained from documented 
obstetric records, not maternal recall, minimizing bias. General limitations 
include not having information concerning gestational age and the socio-
economic status of individual families. Gestational age, a factor reflecting 
foetal growth, has been found to be a predictor of future psychiatric morbidity. 
In particular, being small for gestational age, reflective of reduced foetal 
growth, has been associated with increased schizophrenia risk (Nielsen et al., 
2013). The study was confined to the investigation of birth weight since other 
obstetric information was limited, particularly among subjects born in the 
1940s and 1950s and subjects born at home. Thus, the direct evaluation of the 
association between other potentially relevant obstetric events, including 
APGAR score, infections during pregnancy, pre-eclampsia and gestational 
diabetes, in relation to the investigated outcome measures was not possible. A 
broader scope would have furthered understanding of the causal mechanisms 
driving the association between birth weight and the outcome measures 
investigated. The Finnish schizophrenia family cohort presented the 
opportunity to investigate the relationship between birth weight and 
schizophrenia in an older study sample with an elevated genetic loading for 
schizophrenia, in which the majority of birth weight data were from the 1940s 
and 1950s. Many other studies have investigated the association of obstetric 
complications and schizophrenia risk in younger cohorts. However, due to 
advances in obstetric care over the decades, it is postulated that the pre- and 
perinatal complications associated with neonatal mortality/morbidity may 
have been different in older birth cohorts. High mortality of LBW subjects in 
older cohorts (Rantakallio, 1969) is suggested to have hindered the ability to 
detect an association between LBW and schizophrenia risk in the study 
sample, a finding which has been extensively reported in the literature 
(Cannon et al., 2002a; Abel et al., 2010). Other limitations include lack of a 
control group with no genetic loading. Due to the high genetic loading for 
schizophrenia in our study sample, direct extrapolation of findings in relation 
to the general population cannot be made. However, Keskinen et al. (2013) 
found in the population-based Northern Finland 1966 cohort that high birth 
weight was a risk factor for schizophrenia only in families where the parent(s) 
had a psychotic disorder, which is consistent with our findings. 
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7.(CONCLUSIONS(
In this study, an association was observed between HBW (> 4000 g) and 
increased schizophrenia risk among offspring, in line with previous reports 
describing an association between HBW and both schizophrenia (Hultman et 
al., 1997; Gunnell et al., 2003; Bersani et al., 2007; Moilanen et al., 2010; 
Keskinen et al., 2013) and ASDs (Abel et al., 2013; Byars et al., 2014). Evidence 
of a putative gene-environment interaction between NDE1, a gene implicated 
in neurodevelopment (Bradshaw, 2016), and HBW was detected in association 
with increased schizophrenia risk. Furthermore, a relationship was observed 
between both decreasing and increasing birth weight and the increasing 
severity of disorganized and negative symptoms and decreasing cognitive 
functioning.  
 
Schizophrenia is associated with heritability estimates of up to 81%, implying 
that both genetic and environmental factors moderate schizophrenia risk 
(Sullivan et al., 2012). The association of various independent genetic 
(Schizophrenia Genomics Consortium, 2014) and obstetric complications in 
relation to schizophrenia risk is widely acknowledged (Cannon et al., 2002a). 
Individuals who develop schizophrenia are speculated to be genetically more 
susceptible to the impact of various environmental factors, which exert their 
effect during the neurodevelopmental process (Insel, 2010). However, the vast 
majority of individuals presenting with genetic susceptibility who are exposed 
to environmental adversity do not develop schizophrenia. The reason for this 
has been suggested to be that schizophrenia susceptibility is typically not 
conferred by a single gene or a single environmental factor, but rather by the 
cumulative influence of multiple susceptibility genes interacting with multiple 
environmental factors over the course of time. Although many individual 
genetic and environmental factors have been associated with increased 
schizophrenia susceptibility, less is known about factors underlying resilience, 
which provides protection against the development of the disorder (Rutter et 
al., 2006). Despite increasing knowledge of both genetic and environmental 
risk factors associated with schizophrenia risk, fundamental questions 
regarding the causal pathways remain unanswered. The ultimate question is 
as follows: can the acquisition of this information in relation to the 
longitudinal accumulation of risk factors be utilized in a clinical setting to 
predict the probability of an individual developing schizophrenia and to aid in 
the discovery of preventative treatment strategies?  
 
The neurodevelopmental trajectory of schizophrenia posits that schizophrenia 
risk is mediated by the interaction of genetic susceptibility and environmental 
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adversity occurring during the neurodevelopmental process (Insel, 2010). It 
has been suggested that the neurodevelopmental process represents a period 
of elevated susceptibility, during which the cumulative effects of various 
environmental factors may lead to an incrementally increasing disruptive 
effect on this process (Insel, 2010). The neurodevelopmental model is 
suggested to be corroborated by clinical observations describing schizophrenia 
as being associated with a longitudinal course, i.e. with the presence of notable 
premorbid signs, symptoms and functional impairment becoming manifest 
years before the onset of overt psychotic symptoms (Häfner et al., 2003). The 
mechanisms by which schizophrenia susceptibility genes and environmental 
factors interact in relation to the longitudinal course of schizophrenia remain 
largely hypothetical and unsubstantiated. 
 
Individuals who develop schizophrenia have been suggested to be more 
vulnerable to the effects of pre- and perinatal factors, such as hypoxia and 
infection, than the general population (Nicodemus et al., 2008; Clarke et al., 
2009). The association between HBW and increased schizophrenia risk in the 
present sample, presenting with elevated genetic susceptibility for 
schizophrenia (Hovatta et al., 1997; Hovatta et al., 1999; Ekelund et al., 2001; 
Hennah et al., 2003), corroborates recent reports suggesting that the 
association between HBW and schizophrenia may be moderated by genetic 
liability (Keskinen et al., 2013). The association also suggests that variants of 
NDE1, a gene implicated in neurodevelopment (Hennah et al., 2007; Tomppo 
et al., 2009), may interact with HBW with potential consequences on the 
neurodevelopmental trajectory. The functions of NDE1 may thus be vulnerable 
to the influence of environmental factors associated with HBW. Although 
speculative, the association between HBW and schizophrenia in the current 
study may be related to perinatal hypoxia upon delivery of a HBW neonate.  
 
Patients with schizophrenia typically present with cognitive impairment 
(Keefe and Reichenberg, 2014). Similar, but more subtle cognitive impairment 
has been found in first-degree relatives of patients with schizophrenia (Tuulio-
Hendriksson et al., 2003). The observation that both decreasing and 
increasing birth weight is associated with increased severity of disorganized 
and negative symptoms and decreased cognitive functioning suggests that 
these manifestations are proximal to the neurodevelopmental origins of the 
disorder (Tsuang et al., 2000), in contrast to symptoms of reality distortion, 
which appear to be more peripheral in relation to this trajectory. 
 
From a clinical perspective, knowledge that pre- and perinatal factors are 
associated with an increased risk of future psychiatric morbidity, particularly 
in combination with elevated genetic susceptibility, emphasizes the need for 
the health care system to better recognize and address this widely replicated 
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association. However, identification of at-risk individuals before the advent of 
genetic testing can only be based on familial history of psychiatric morbidity. 
Evidence suggests that women with schizophrenia have fewer antenatal care 
visits during pregnancy (Bennedsen et al., 2001), which in itself represents a 
factor associated with increased schizophrenia risk among offspring (Byrne et 
al., 2007). The British National Institute of Health and Care Excellence (NICE) 
guideline regarding antenatal and postnatal mental health (Howard et al., 
2014) recommends the implementation of an integrated care plan for women 
presenting with psychiatric disorders during pregnancy. In the plan, the roles 
of each of the respective health care providers are clearly defined, starting from 
the implementation of a monitoring schedule and designation of the provider 
responsible for coordination of the plan. The aim of the plan is to ensure that 
each participant involved acknowledges their specific responsibilities and that 
information concerning the patient is shared effectively.!In Finland, a national 
guideline addressing the integrated role of different health care providers in 
the antenatal care of women with severe psychiatric disorders has not yet been 
established. Construction of such a Finnish national guideline is suggested to 
promote co-operation of psychiatric, antenatal and obstetric services to 
establish a foundation relative to which the integration of these services may 
be strengthened for the benefit of Finnish women with severe mental disorders 
and their children.  
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8.(FUTURE(AREAS(OF(INVESTIGATION(
Although the current study has focused on the association between pre- and 
perinatal factors in relation to schizophrenia risk, it must be emphasized that 
the in utero environment has also been investigated in relation to the 
development of various other psychiatric disorders including depression 
(Räikkonen et al., 2012).  
 
The increasing sample size of future GWASs may replicate previous findings 
and enable the detection of novel genes mediating schizophrenia risk, thus 
aiding in the formulation of novel hypothesis-driven approaches for the 
analysis of future gene-environment interactions.  
 
The investigation of environmental factors in relation to gene-environment 
interaction analyses will require more validation with respect to the qualitative 
and quantitative nature of the environmental factor under consideration 
(Caspi et al., 2010). For instance, childhood adversity is a very broad term, 
encompassing a multitude of adversities of variable intensity and duration, 
and thus, specification of what exactly is being measured will increase the 
validity of findings and facilitate the replication of gene-environment 
interaction studies, which is a prerequisite for further large-scale 
investigations. The validation of environmental factors within a specific cohort 
will also require greater understanding of the demographic considerations of 
the sample and how these demographic factors differ in relation to separate 
populations and are subject to change over time. For instance, the 
epidemiological characterization of potential causal factors underlying the 
association between birth weight and schizophrenia is complicated by 
evidence suggesting that the influence of potential causal factors may change 
as a function of time, particularly in relation to both changes in the nutritional 
status of a population (Yamada et al., 2014) and advances in obstetric practice 
and neonatal care (The official statistics of Finland XI: 62, 1962; Hemminki, 
1983; Piekkala et al., 1986; Pitkänen et al., 2000). Understanding the 
demographic considerations of a specific study sample may facilitate the 
verification of hypotheses concerning causality.  
 
The present study corroborated previous findings implicating an association 
between the in utero environment and future psychiatric morbidity, in this 
case the associations between birth weight and schizophrenia risk, symptom 
severity and cognitive functioning, which are likely moderated by the 
interaction of genetic susceptibility and early environmental adversity. More 
information on pre- and perinatal factors needs to be collected in order to 
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elucidate the causal mechanisms. The use of serum samples to directly assess 
the presence of a potential biomarker in relation to schizophrenia risk has 
already been employed. This has resulted in the discovery of an association 
between the nicotine concentration of maternal serum during pregnancy and 
increased schizophrenia risk among offspring (Niemelä et al., 2016). A study 
investigating the association between maternal infection at the time of 
pregnancy and the risk of psychosis in offspring, reported an association 
between elevated maternal immunoglobulin levels against Toxoplasma gondii 
and cytomegalovirus and decreased levels of neonatal acute phase proteins, in 
relation to the increased risk of non-affective psychoses among offspring 
(Blomström et al., 2015). This finding was suggested to reflect an association 
between maternal chronic infection and deficient foetal immune system 
responses, in relation to increased risk of psychosis.  
 
In addition to pre- and perinatal factors, schizophrenia risk is also mediated 
by postnatal factors, including psychosocial factors associated with childhood 
adversity, and cannabis use (Caspi et al., 2005; Alemany et al., 2011; Aas et 
al., 2014; Hollander et al., 2016). Prospective cohorts of increasing size are 
being collected to shed light on the role of parental behaviour in relation to 
childhood development (Nolvi et al., 2016) and will allow a more 
comprehensive understanding of the causal relationships in relation to the 
longitudinal trajectory of the disorder. Further characterization of the impact 
of postnatal factors and their contribution to overall schizophrenia risk in 
combination with the influence of both genetic and pre- and perinatal risk 
factors may in the future present an opportunity to define a clinically relevant 
polyfactorial risk score, with the potential to predict schizophrenia risk, thus 
having possible implications for prevention of disease progression.!
 
The identification of genetic variation does not take into account factors 
related to protein expression. Finding a susceptibility gene is analogous to 
finding an instruction manual on “how to make a car”. Although you have 
gained access to the instructions and have knowledge of the endpoint, i.e. the 
car model you want to make, you are still far from understanding the practical 
considerations involved in each step of the process. One step in furthering our 
understanding of what lies between the gene-phenotype continuum will 
require the utilization of proteomics to complement genetic and epigenetic 
research (Nascimento et al., 2016). The study of epigenetics in psychiatric 
research has gained increasing momentum and will potentially allow the 
elucidation of the role of gene expression in psychiatric morbidity (Hannon et 
al., 2016). However, gene expression levels will not give substantial insight 
into processes of protein function, which include post-translational 
modification of proteins (e.g. processes related to protein glycosylation), the 
trafficking of proteins to appropriate intra- or extracellular destinations and 
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the interaction of proteins with other proteins. Moreover, proteins often 
function as complexes, and thus, knowledge of the functions of one component 
will not necessarily reveal the functions of the complex as a whole. A protein 
is the ultimate product of gene-environment interaction, and focusing on the 
biochemical, cellular, histological and neurophysiological aspects of protein 
functioning is necessary to gain further insight into the causal aetologigical 
mechanisms underlying psychiatric disorders. Recently, various tissue-
specific biobanks have been established, including brain biobanks, consisting 
of brain tissue samples in which protein localization can be investigated 
(Palmer-Aronsten et al., 2016). However, the use of animal models will still be 
required to assess protein functioning in a physiological setting (Sekar et al., 
2016).  
 
Schizophrenia represents a highly heterogeneous phenotype, and 
schizophrenia risk is likely to be mediated by the interaction of numerous 
genetic and environmental factors, each of which independently presents with 
small individual effect size. Genetic variants of large effect size may increase 
the probability of detecting a gene-environment interaction. The use of 
intermediate phenotypes, in combination with genetic variants with large 
effect sizes, may further facilitate the detection of environmental factors 
mediating psychiatric morbidity and shed further light on the biological 
mechanisms involved in neurodevelopment. It is suggested that focusing on 
the intermediate phenotypes associated with variants of the DISC1 network, 
rather than schizophrenia as an endpoint, may continue to provide valuable 
information on the neurodevelopmental underpinnings of psychiatric 
morbidity.   
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